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CHAPTER 1 
INTRODUCTION 

MULTIPLE SCLEROSIS 
Multiple sclerosis (MS) or disseminated sclerosis is ал inflammatory demyelinating 
disease of the central nervous system (CNS) of an unknown origin. The disease is 
characterized by multiple lesions disseminated throughout the CNS in both time and 
space. The essential MS lesion is the plaque, a more or less circumscribed lesion varying 
in size and orientated around venules. The characteristic changes in the plaque itself are 
loss and destruction of myelin with relative preservation of axon continuity, and gliosis. 
The first classic descriptions of the disease were made by Cruveilhier (1829-1842) and 
Charcot (1868). The prevalence of MS in northern european countries and northern 
United States is about 30-80 per 100,000 inhabitants. MS occurs with a higher frequency 
as the distance from the equator increases. There is a distinct predilection for temperate 
climates and for economically developed countries. Very high prevalences are reported 
from the Orkneys, Shetland Islands, and Finland (100-250/ 100,000 inhabitants). In the 
Netherlands the prevalence of MS is 60 per 100,000 inhabitants and it is the most 
common neurological disorder in young adults (de Graaf et al., 1988). About two-third of 
the MS patients have the onset of their disease when they are between 20 and 40 years 
old. The incidence of MS is higher in women than in men, varying from 3:2 to 2:1 
(Acheson, 1977; Kurtzke et al., 1979). 
The criteria for the clinical diagnosis of MS have been changed over the years (Schuma­
cher et al., 1965; McAlpine et al., 1972; Rose et al., 1976; McDonald and Halliday, 
1977; Poser et al., 1983). The basis of the clinical diagnosis according the Schumacher 
criteria is the establishment of (1) evidence of signs and symptoms of dysfunction in the 
CNS that can not be explained by one single lesion (dissociation in space), (2) evidence of 
such occurrences at different times in the patient's life (two or more attacks, lasting at 
least 24 hours, and separated by at least a month) or progression over more than six 
months (dissociation in time), (3) objective neurologic signs present on examination, (4) 
the signs and symptoms must be explained by white matter lesions, (5) the absence of 
evidence suggesting that such multiplicity of lesions in space and time could be explained 
by any other common causes of multiple lesions, and (6) when the patient is between 10 
3 
and 50 years old. Patients were classified as "clinically definite" MS if they met five or 
six criteria. Patients who satisfied fewer criteria were categorized as "probable" or 
"possible" MS. The Schumacher criteria do not incorporate supportive laboratory data 
into the diagnostic criteria. In the last two decades (in the 1970s and 1980s) several 
laboratory and clinical methods have become available, which permit the demonstration of 
lesions that were hitherto clinically silent and undetectable (evoked potential studies, 
urological studies, magnetic resonance (MR) imaging). The criteria of Poser et al. (1983) 
allow to incorporate these new supportive laboratory data. The Poser criteria are at 
present the most widely used for the diagnosis of MS and create a more up-to-date 
guideline for research protocols. The new diagnostic criteria according to Poser et al. 
(1983) are summarized in Table 1. 
Table 1. New Diagnostic Criteria for Multiple Sclerosis (Poser et al., 1983). 
Category 
A. Clinical definite 
CDMS Al 
CDMS A2 
B. Laboratory-supported 
definite(LSD) 
LSDMS Bl 
LSDMS B2 
LSDMS B3 
С Clinically probable 
CPMS CI 
CPMS C2 
CPMS C3 
D. Laboratory-supported 
probable 
LSPMS Dl 
Attacks 
2 
2 
2 
1 
1 
2 
1 
1 
2 
Clinical 
evidence 
2 
1 
1 
2 
1 
1 
2 
1 
and 
or 
and 
and 
Paracl inical 
evidence 
1 
1 
1 
1 
CSF 
OBflgG 
+ 
+ 
+ 
+ 
Legend: CD = clinical definite; LSD = laboratory-supported definite; CP = clinically probable; 
LSP = laboratory-supported probable; OB/IgG =oligoclonal bands/ increased IgG. 
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rhe disease course of MS is highly variable. Four major patterns can be separated. 
Patients with relapsing-remitting (RR) form have exacerbations of dysfunction which 
resolve completely or nearly completely. About 2596 fall under this category. The 
relapsing-remitting type with chronic progression (CP+RR), or secondary progressive 
type, seen in about 40% of the patients, is similar to the RR disease, but recovery after 
exacerbations is clearly incomplete and disability increases gradually. A minority of MS 
patients (5-15%) have slowly evolving chronic progression (CP) of neurological deficits 
from the onset without relapses and remissions. Benign MS is referred to patients with 
minor disability (Kurtzke's Expanded Disability Status Scale/ EDSS-score of 3 or less) 
despite years of illnes (10 years or more). About one-third of patients with RR disease are 
in this category. Predicting the disease course and prognosis in the individual MS patient 
is nearly impossible. Generally, female sex, onset of disease at a young age (before 35-40 
years) with sensory symptoms, and relapsing-remitting disease course are associated with 
a better prognosis. Late onset of disease accompanied with cerebellar or motor signs, 
short first inter-relapse interval are supposed to be characteristics of a bad prognosis (de 
Graaf et α/., 1988; Minderhoud et ai, 1988). 
The most common initial clinical manifestations are sensory complaints (21-55%), motor 
symptoms (corticospinal tract involvement 32-41%), brainstem symptoms (40-70%), optic 
nerve symptoms (14-23%), cerebellar manifestations (13%), sphincter and sexual 
disturbances (10%) (Matthews, 1991; Kurtzke, 1970). Excessive fatigue is an other 
common complaint of MS patients. Freal et al. (1984) reported this symptom in 78% of 
patients. Cognitive and psychiatric disturbances may occasionally be the initial symptom 
in MS (Young et al., 1976); in recent years more attention is drawn to these disturbances 
(Ron and Feinstein, 1992). Typically in MS is that signs and symptoms can wax and 
wane. 
PATHOLOGY 
The pathological characteristics in MS are a selective destruction and loss of the myelin 
sheaths with relative sparing and preservation of the axons in the CNS. Active lesions are 
5 
characterized by mononuclear cell infiltrates around venules and small veins (perivascular 
cuffs). These cells account for the perivascular inflammation and increased cellularity. 
The perivascular cuffs contain a mixed cellular population in which T-cells, macrophages 
and some plasma cells are present (Traugott et al., 1983). Myelin disintegration and 
myelin breakdown products have been found in the early phase of active plaques (Adams, 
1983; Lumsden, 1970). The lesion may vary in diameter from less than a millimeter to 
several centimeters. Contrasting views are held about the initial and earliest or primary 
histological abnormalities in the development of new lesions. Acute MS lesions have been 
reported in which perivascular lymphocyte cuffs are minimal, indicating myelin 
breakdown without increased cellularity (Lumsden, 1970; Prineas, 1985). 
Adams (1977, 1983) and Prineas and Raine (1976) found that lymphocytic infiltration 
precede the process of myelin breakdown. Old inactive lesions consist of demyelinated 
axons, are gliotic and hypocellular and show massive oligodendrocytic loss. Remyeli-
nation in acute lesions has been described (Prineas et al, 1987). In chronic lesions 
remyelination is frequently seen with formation of new myelin simultaneously with 
demyelination resulting in "shadow plaques" in which there are thinly remyelinated axons 
(Prineas and Connell, 1978, 1979; Prineas et al., 1984). Active lesions are characterized 
by a hypercellular edge within macrophages and hypertrophied astrocytes are seen in the 
presence of myelin breakdown. At present blood brain barrier (BBB) disruption in 
association with inflammation is thought to be one of the first events in the development 
of the acute MS lesion (Hawkins et al., 1991). This stage can be visualized by 
gadolinium-enhanced magnetic resonance imaging (MRI) of the brain. In a neuro-
pathological study (Katz, 1990) of a patient who died unexpectly after gadolinium-
enhanced MRI, enhancing lesions showed clear perivascular inflammation. 
Different stages or pathological processes can be distinguished in the development of MS 
lesions (Hommes, 1989); the exact sequence of events is unknown. The different stages 
are: - 1 - blood brain barrier (BBB) disruption in association with immune activation, - II 
- perivascular infiltration of competent cells, - III - demyelination, - IV - remyelination, 
and - V - scarformation with gliosis and axonal loss. 
6 
rhe demyelinatìng diseases of the CNS can be classified in different groups and types 
(Table 2). MS (Charcot type) is the most common demyelinating disease. The most 
common distribution of MS lesions in the brain is periventricular (in both hemispheres 
roughly equally distributed), particularly to the lateral angles of the lateral ventricles, the 
periaqueductal region and the bottom of the fourth ventricle. Other favorite localisations 
are the optic nerve, brainstem and spinal cord. Brownell and Hughes (1962) found that 
74% of the MS lesions were in the white matter, 17% were sited subcortical, 5% were 
cortical and 4% were sited in the central grey matter. Of all cerebral lesions 22% were 
frontal, 15% parietal, 12% temporal and 1% occipital. Lumsden (1970) found that in a 
serie of 10 cases (early acute) with a total of 482 lesions, 58% were sited cortical, 13% 
in the centrum semiovale and corpus callosum, 9% in the basal ganglia, 4% in the 
midbrain, 6% pontine, 6% cerebellar, and 3% medullary. 
Table 2. Demyelinating diseases of the central nervous system (CNS). 
MS - classic (Charcot type) 
Variants - Marburg (acute sclerosis) 
- Baló (concentric sclerosis) 
- Schilder (diffuse cerebral sclerosis) 
- Dévie (neuromyelitis optica) 
Acute disseminated encephalomyelitis (ADEM) 
- classic (para-infectious; postimmunisation; idiopathic) 
- hyperacute (acute haemorrhagic necrotizing leucoencephalitis) 
Progressive multifocal leucoencephalopathy (PML) 
Subacute combined degeneration (SCD) of the cord (vitamin B12 deficiency) 
Central pontine myelinolysis 
Subcortical arteriosclerotic encephalopathy 
Posthypoxic and periventricular leucoencephalopathy 
Subacute sclerosing panencephalitis (SSPE) 
HTLV-1 associated myelopathy 
Intoxications (Hg, Pb, cytostatics, radiation-therapy, toxic-metabolic processes) 
ETIOLOGY 
The cause of MS is unknown. At present no etiological hypothesis explains satisfactorily 
the cause of the disease. Prevailing hypotheses suppose that MS is the result of a 
7 
persistent infectious agent (virus?) in susceptible individuals or that MS results from an 
immune-mediated process directed against myelin antigens initiated by a transient 
infectious agent (Booss and Kim, 1990). Lines of evidence for these hypotheses are the 
neuropathology of the demyelinating MS lesion which resembles the lesions caused by a 
number of viral infections in different demyelinating diseases (e.g. SSPE, PML, ADEM). 
The hypothesis of an infectious agent is supported by epidemiological studies, e.g. the 
geographically distribution of MS and migration studies (Kurtzke et al., 1979). However, 
sofar no particular infectious agent has been found in MS. Other studies have revealed a 
clear genetic influence of susceptibility to MS. Ebers et al. (1986) found in monozygotic 
twins a concordance rate of 26% compared with 2.3% in dizygotic twins and 1.9% for 
brothers and sisters. Certain histocompatibility antigens (HLA) are more frequent in MS 
patients (HLA- A3, -B7, -Dw2). Other etiological possibilities are that MS is an auto-
immune disease with dysregulation of the immune system (McFarlin and McFarland, 
1982; Weiner and Hafler, 1988) or that the process of demyelination in MS represents a 
nonspecific consequence (bystander effect) of a cell-mediated immune response. 
In conclusion, the pathogenesis and etiology of MS is still obscure, but there is circum-
stantial evidence that MS is an immune-mediated disease in genetically susceptible 
individuals in relationship with environmental factors. 
TREATMENT 
Although the pathogenesis and etiology of MS is unknown, at present most therapies 
applied in MS and in clinical MS treatment trials are anti-inflammatory, immunosuppres-
sive or immunomodulatory agents. Table 3 summarizes various applied treatments in MS. 
Other forms of treatment or other strategies are e.g. oral administration of antigen (MBP) 
which can down regulate experimental auto-immune disease through oral tolerance 
(Higgins and Weiner, 1988); the application of extracorporeal photochemotherapy 
(PUVA-psoralen ultraviolet A), which has distinct immunological effects (Okamoto, 
1987); dietary treatment, especially the use of unsaturated acids and gluten-free diet; 
hyperbaric oxygen (Bates, 1986); 4-aminopyridine, a potassium channel blocker, which 
8 
Introduction 
restores conduction in demyelinated nerves (Stefoski et al., 1987; Diemen et al., 1992). 
In general, some immunosuppressive agents seem to have positive effects in patients with 
MS; in contrast augmentation of the immune response, e.g. with gamma-interferon, 
results in clinical deterioration (Panitch, 1987). 
In the last four decades, corticosteroids and corticotrophin (ACTH) have become quite 
commonly used to treat exacerbations and clinical progression in MS. After preliminary 
studies by Jonsson et al. (1951), and Glaser and Merrit (1952), who suggested that 
ACTH might have a beneficial effect in MS, the first randomized placebo-controlled 
study with ACTH was in 1961 by Miller et al. (1961a). 
Table 3. Overview of the most applied therapeutic agents in MS. 
Corticosteroids and corticotrophin (ACTH) 
Cyclophosphamide 
Azathioprine 
Cyclosporine 
Interferon 
Total lymphoid irradiation (TLI) 
Plasma exchange (PE) 
Monoclonal antibodies 
Copolymer-I 
Lymphocytapherese 
Colchinine 
Immunoglobulins 
They found that intramuscular ACTH was more effective in relapsing MS patients than 
placebo-treated control patients. These results were confirmed in 1970 in a large 
multicenter cooperative study (Rose et al., 1970). Chronic use of oral corticosteroids 
seemed to be less effective in the treatment of MS (Miller et al., 1961b; Fog, 1965; 
Tourtellotte and Haerer, 1965). 
In the 1970s a new agent was introduced and a new mode of administration was used: 
high-dose intravenous methylprednisolone (IVMP). Several studies reported beneficial 
effects of this therapy regimen in patients with internal immune-mediated diseases 
ς 
(Cathcart et al, 1976; Gray et al, 1978). For this reason IVMP treatment was attempted 
in relapsing MS patients. After that period several uncontrolled and open studies 
(Dowling et al., 1980; Trotter and Garvey, 1980; Buckley et al, 1982; Goas et al, 
1983; Newman et al, 1982; Troiano et al, 1987) showed that IVMP accelerated clinical 
improvement after acute exacerbations and that the clinical improvement was better after 
IVMP. Table 4 summarizes the different controlled and randomized studies using IVMP 
in the treatment of MS. Ohno et al (1987) suggested in his retrospective study that IVMP 
might be more effective in acute exacerbations of MS than oral prednisolone treatment. 
The present evidence seems to suggest that courses of IVMP appear to be the best agents 
in the treatment of acute relapses of MS (Compston, 1988; Troiano et al, 1987). 
However, the effects of IVMP in the course of chronic progressive MS have been less 
equivocal, but there is some evidence that it is beneficial (Ellison et al, 1988; Citterio et 
al, 1987; Milligan et al, 1987). At present a lot of questions remain about the optimum 
dose of MP, duration of therapy, and whether or not a tapering dose after the initial 
course is needed. 
Analysis of the side-effects of IVMP indicates a good tolerance and safety. Relatively few 
complications have been observed. Lyons et al. (1988) analysed 350 IVMP treatments 
given to 240 MS patients. The standard regime was 1000 mg MP daily for 5 consecutive 
days, intravenously administered. Table 5 shows the total number of side-effects divided 
into minor effects and significant complications. An acute anaphylactic reaction has been 
described in 1 patient (Pryse-Phillips et al, 1984). Warren et al (1986) using 2 gram 
IVMP for 10 days, recorded acute psychosis, steroid-induced cataract, and necrosis of the 
femoral head. As opposed to the short courses with high-dose IVMP, the use of oral 
chronic low dose prednisolone in chronic progressive MS disease is encountered with a 
high incidence of side-effects, including hypomania, osteoporosis, hypertension and 
pathological fractures (Tourtellotte and Haerer, 1965). Intrathecally administered MP is 
attended with serious complications, such as adhesive arachnoiditis, paraparesis and 
pachymeningitis, hence this form of administration is not recommendable (Nelson et al, 
1973;Bemat«a/., 1976). 
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ІЪе exact mode of action of IVMP and corticosteroids in relapsing and progressive MS is 
uncertain. Possible mechanisms (Miller et al., 1992) include resolution of edema, 
decrease of inflammation and restoration of the blood-brain barrier (BBB) disruption; a 
direct neuro-physiological effect with improvement of nerve conduction; and an 
immunologically mediated effect with reduction of intrathecal IgG synthesis, decrease of 
Г-lymphocytes, and ultimately reduction of myelin breakdown with decrease of CSF 
myelin basic protein. 
Table 5. Minor side effects and significant events during 350 courses with IVMP in 240 MS 
patients (Lyons et al., 1988). 
Minor effects 
(not quantified) 
Significant events 
(number) 
Transient facial flushing 
Metallic taste 
Distal paraesthesiae 
Insomnia 
Mild weight gain 
Minor infections 
Hyperglycaemia 
gastro-intestinal 
symptoms 
Psychiatric 
symptoms 
Epilepsy 
Others 
urinary tract (2) 
oral candidiasis (1) 
vaginal candidiasis (1) 
no intervention (11) 
insulin 1 year later (1) 
dyspepsia (S) 
duodenitis (1) 
euphoria (4) 
depression (2) 
acute psychosis (1) 
concomitant seizure (1) 
early delay (1) 
late delay (1) 
acne exacerbation (3) 
ankle oedema (2) 
pressure sore (1) 
extravasation of 
injection (1) 
transient hypertension (1) 
deep vein thrombosis (1) 
OUTLINE OF THIS THESIS 
The general aim of this thesis is to evaluate the effect of IVMP on various disease 
/ariables (clinical and paraclinical) in MS patients. The effect of IVMP on clinical 
1? 
Introduction 
disability (expressed by Kurtzke's Expanded Disability Status Scale- EDSS score), various 
CSF and PB variables (especially CSF MBP, IgG and IgM measurements), and the effect 
on gadolinium-enhanced MRI (as a marker of disease activity in MS) have been inves-
tigated (Barkhof, 1992; McFarland et al., 1992). Further investigation is focused on 
whether IVMP influence the course of MS at the long term or not. 
The first section of this thesis (Chapter 2) describes the effect of IVMP on CSF MBP and 
on IgG and IgM measurements in the CSF and PB of relapsing and chronic progressive 
MS patients. Prior to the IVMP course the CSF and PB variables are analysed to 
determine whether a significant correlation could be obtained with clinical disability and 
other clinical parameters. In Chapter 3 the same analysis as the one mentioned above is 
done for cellular measurements (T- and B- lymphocytes). 
Because several recent studies (Surtees et al., 1991; Reynolds et al., 1991 ; Nijst et al., 
1990) have indicated an association between low levels of vitamin B,2 in MS and a 
relationship between vitamin Bl2/folate metabolism and (dys-)myelination, the effect of 
IVMP was investigated on these vitamin levels (Chapter 4). 
Chapter 5 reports the relationship between the clinical and gadolinium-enhanced MRI 
findings in MS patients; whether gadolinium-enhanced MRI might be useful in monitoring 
disease activity in MS (e.g. during studies of putative therapeutic agents). 
Chapter 6 and 7 deal with the evaluation of IVMP in MS, whether changes in gadolinium 
enhancement on MRI correlate with changes in clinical findings and various CSF 
variables. At the same time Chapter 7 gives a short survey of the literature about the 
evaluation of IVMP therapy in MS by (gadolinium-enhanced) MRI. 
The last part (Chapter 8 and 9) of this thesis discusses the long-term evaluation of IVMP 
treatment in MS, assessed by long-term MRI follow-up, clinical evaluation and various 
CSF measurements during the follow-up period. 
In the closing Chapter 10 the findings described in this thesis are summarized and 
discussed. 
13 
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CHAPTER 2 
CEREBROSPINAL FLUID MYELIN BASIC PROTEIN, IgG AND IgM LEVELS IN 
101 MULTIPLE SCLEROSIS PATIENTS BEFORE AND AFTER TREATMENT 
WITH HIGH-DOSE INTRAVENOUS METHYLPREDNISOLONE 
S.T.F.M. Frequin, F. Barkhof, K.J.B. Lamers, O.R. Hommes, G.F. Borni 
ACTA NEUROL SCAND 1992; 86: 291-297 

Methylprednisolone/CSF analysis in MS 
Introduction 
Nowadays high dose intravenously administered methylprednisolone (MP) has an 
established role in the treatment of multiple sclerosis (MS) (Compston, 1988; Troiano et 
al., 1987). In relapsing multiple sclerosis patients a significant decrease in clinical 
disability scores compared with controls (Durelli et al., 1986), placebo (Durelli et 
al., 1986; Milligan et al, 1987) or other therapy regimens (Barnes et al., 1985) is 
reported after MP treatment. A reduction is found in contrast enhancement of MS plaques 
on CT-scan (Troiano et al., 1984) and recently also in gadolinium-DTPA enhancement on 
MRI (Barkhof et ai, 1991), all suggesting that restoration of the Blood Brain Barrier 
(BBB) integrity is improved or accelerated after MP. 
There have been relatively few reports discussing the effects of intravenously 
administered MP on cerebrospinal fluid (CSF) parameters in MS. A reduction in 
intrathecal IgG synthesis, myelin basic protein (MBP), anti-MBP, and anti-MAG (myelin 
associated glycoprotein) is reported (Tourtellotte et al., 1980; Tourtellotte et al., 1982; 
Compston et al., 1987; Baumhefner et al., 1989; Warren et al, 1986; Warren et al, 
1987; Wajgt et al, 1983). Qualitative IgG abnormalities, i.e. oligoclonal banding (OB) 
on iso-electric focusing (IEF) seems to be uninfluenced (Durelli et al, 1986; Tourtellotte 
et al, 1980; Tourtellotte et al, 1982; Trotter and Garvey, 1980). How exactly the 
immune response and myelin breakdown in MS are tempered or influenced by MP 
treatment is unclear. We studied the effect of MP treatment on CSF MBP and 
immunoglobulin levels in 101 MS patients and the relation between CSF MBP and 
immunoglobulin levels. 
Materials and Methods 
101 consecutive MS patients ( 62 females ; 39 males) with clinically definite MS (CDMS) 
or laboratory supported definite MS (LSDMS), according to the criteria of Poser et al. 
(1983), who presented to the Department of Neurology of the University Hospital in 
Nijmegen with a symptomatic deterioration, were studied between 1988 and 1990. Mean 
age and disease duration (DD) was 35.4 (range 22-58) and 8.8 (range 0.7-24.8) years, 
25 
respectively for the females; 35.2 (range 21-50) and 7.3 (range 0.3-23.0) years, 
respectively for the males. All patients had a symptomatic deterioration and were 
classified to disease course : chronic progressive (CP) - 47 patients, relapsing remitting 
(RR) - 37 patients, and a combination (CP+RR) - 17 patients. A relapse was defined as a 
symptomatic deterioration with the occurrence of one or more new symptoms or 
worsening of existing symptoms of less than 8 weeks but lasting longer than 24 hours 
without evidence of spontaneous improvement. A chronic progressive (CP) disease course 
was determined as a continuous symptomatic deterioration of neurological symptoms for 
at least 6 months. CP+RR was the combination of a chronic progressive disease course 
accompanied by relapses and remissions. All patients in the RR and CP+RR group had a 
relapse at the time at entrance into the study. No patient had used immunosuppressant 
agents 6 months or longer prior to entrance. 
Reference values for CSF parameters were determined in a group of 35 patients (18 
females, mean age 41.2, range 15-66 years; 17 males, mean age 45.0, range 17-65 years) 
with psychoneurosis without evidence of any organic, infectious or auto-immune 
inflammatory neurologic disease. The diagnoses were conversion disorders, tension 
headache and nervositas. 
The patients were treated with 1000 mg MP daily for 10 consecutive days administered 
intravenously between 09.00 and 10.00 A.M. during approximately 15-20 minutes. No 
tapering dose was used. Therapy was tolerated well. Four major side-effects occured: one 
epileptic seizure, one exacerbation of chronic bronchitis, one herpes zoster infection, and 
one peptic ulcer. Immediately before and after MP treatment blood samples and CSF taps 
were obtained simultaneously. Clinical scoring was performed according Kurtzke's 
Expanded Disability Status Scale (EDSS) (Kurtzke, 1983) before and after MP treatment 
simultaneous with the blood and CSF examination by an examiner (S.T.F.M.F.) who was 
unaware of the CSF findings. 
Peripheral venous blood and CSF samples were drawn according to standard procedures. 
Samples of blood and CSF were stored within 30 minutes at -70 С until assayed. IgG and 
albumin in unconcentrated CSF were measured by means of an automated kinetic 
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turbidometric method described by Jongen et al. (1990). In brief sheep antihuman IgG 
(Boehringer, Mannheim, FRG) and rabbit antihuman albumin (Behringwerke AG, 
Marburg/Lahn, FRG) were used. Serum was always diluted (1:400) with saline, and both 
specimens (CSF and serum) were run in the same batch. IgM in CSF was measured by an 
ELISA method. Plates were coated with 150 μΐ/well, 1/500 diluted rabbit anthuman IgM 
in PBS-buffer, pH 7.4 (DAKO, Copenhagen). CSF, 100μ1 and (1:10) diluted CSF and 
human IgM stan- dards (Behringwerke AG, Marburg/Lahn, FRG) in duplicate were used 
per well. Rabbit peroxidase-conjugated antihuman IgM (DAKO, P125) was used for the 
enzyme reaction. The sensitivity level was 0.05 ng/ml. 
We used the following ratios in analysis : Q Albumin =CSF albumin concentration χ 105/ 
Serum albumin concentration. Q IgG =CSF IgG/Serum IgG. IgG index = Q IgG/ Q 
Albumin. CSF index for IgM was calculated with a similar equation. The calculation of 
intrathecal (de novo) IgG and IgM synthesis was performed according to the hyperbolic 
Reiber Formula (Reiber and Felgenhauer, 1987). 
For iso-electric focusing (IEF) CSF proteins were concentrated in micro-collodion Bag 
type under 1000 kPa nitrogen pressure. A constant amount protein of CSF and diluted 
serum were applied for IEF before and after MP treatment. For IEF paired CSF and 
serum examination was done with ready made LKB Ampholine PAG-Plates (product nr. 
1804-101, pH range 3.5-9.5) and Coomassie blue staining. CSF oligoclonal banding was 
compared with serum. Myelin basic protein (MBP) was determined according to the in­
structions of the manufacturer (Diagnostic Systems Laboratories, Webster Texas USA, 
cat.nr. 1500), using a double antibody radioimmunoassay kit containig human basic 
protein (whole molecule) as antigen and rabbit anti-human MBP as anti-serum. Goat anti-
rabbit gamma globulin was used as MBP precipitation reagent. Human MBP ( J m 2 
jtCi/vial) was included in the test kit. The detection limit was 0.1 ^g/l ; the variation 
coefficient of the assay was 7.5%. 
Statistical analysis 
Data before and after MP treatment were compared by means of Wilcoxon's signed rank 
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test. The Kruskall Wallis test was used for differences between the three disease course 
groups. Relations between CSF data were calculated by means of Spearman's correlation 
coefficient. Hypotheses were tested two sided and p-values smaller than 0.05 were 
considered statistically significant. As data were not complete in all patients, the 
calculations were performed on numbers smaller than 101, but high enough to guarantee 
clear statistical decisions. To avoid crowding the numbers are not mentioned in the tables. 
Results 
Table 1 shows the mean and median values of the clinical scoring (EDSS) and different 
CSF parameters before and after MP treatment for 101 MS patients. Before MP treat-
ment, all mean CSF values, except for Q albumin, were significantly elevated compared 
to reference values. Oligoclonal CSF bands were present in 92.1 % of the patients. Except 
for Q albumin, and IgM index, all CSF parameters decreased significantly after MP 
treatment. In 10 patients the oligoclonal banding pattern completely disappeared after 
treatment. The decrease in EDSS (1.0 point or more) was significantly (p<0.05) 
associated with young age (< 40 years) and short disease duration (< 8 years) and was 
not dependent of the disease course. 
Table 2 gives the results for the three different disease course groups. Before treatment 
the mean CSF MBP levels were significantly (p=0.03) higher in the relapsing remitting 
(RR) and in the combined (CP+RR) group of MS patients compared to the CP MS 
group. CSF IgM (p=0.0145) and intrathecal IgM synthesis (p=0.06) were higher in the 
relapsing remitting (RR) group versus the other 2 groups. After MP treatment only the 
mean CSF MBP levels for the three separate disease course groups of MS patients 
returned to normal values with respect to the reference values, while the mean values of 
all other CSF parameters investigated (except Q albumin) remained elevated. Table 3 
shows the relations between CSF parameters for the whole MS group (n=101 patients). 
Before treatment CSF mononuclear cells were highly correlated with CSF MBP, IgG and 
IgM parameters. Moreover CSF MBP was significantly correlated with IgM parameters. 
IgM parameters were significantly correlated with IgG parameters. 
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Before MP treatment (not in table) EDSS of the total MS group was not significantly 
related with any of the CSF parameters. Only in the relapsing MS group there was a 
trend (p=0.06) towards a positive correlation between EDSS with CSF MBP (r=0.34). 
In the 2 other groups such a correlation could not be demonstrated. 
Following MP treatment (not in table) the decrease in the total CSF mononuclear cells 
was correlated with the decrease in CSF MBP level (r=0.26*'), IgG index (r=0.27*) 
and intrathecal IgG synthesis (r=0.33**). The decrease in CSF MBP was significantly 
correlated with the decrease in IgM index (r=0.30**); a trend (p<0.10) was found 
between the decrease in CSF MBP and lowering in EDSS following MP treatment 
(r=0.18). This correlation was statistically significant in the RR group (r=0.39*) but not 
in the 2 other groups. 
l p < 0 . 0 5 * , ρ<0.01 ** 
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Discussion 
Multiple sclerosis is probably an auto-immune mediated inflammatory demyelinating 
disease from unknown origin. The pathofysiology of MS lesions may be divided in 4 
different stages (Hommes, 1989). Stage I stands for disruption of the blood-brain barrier 
(BBB) and is possible the first step in the demyelinating proces (Kermode et al., 1990). 
Stage II stands for infiltration of lymphocytes and macrophages into the CNS; stage III 
for demyelination/myelin breakdown and stage Г for gliosis and scar formation 
("sclerose en plaques"). Different lesions may be active at different stages simultaneously 
in the same patient (Kermode et al., 1989). 
Corticosteroids (high dose intravenously administered methylprednisolone) can improve 
BBB integrity (stage I) as found by CT scan (Troiano et al., 1984) and gadolinium 
enhanced MRI (Barkhof et al., 1991) and have an immunosuppressive effect (Durelli et 
al., 1986) on the inflammatory proces (stage II). The rationale for immunosuppressive 
treatment is that the amount of myelin breakdown/demyelination (stage III) can be 
tempered or possibly stopped in order to prevent evolution into stage IV. 
In this study we have performed clinical scoring and CSF analysis in MS patients directly 
before and after MP treatment. This gives the opportunity to determine the effects of 
treatment on the different stages of the pathofysiological process of demyelination and to 
make relations between the clinical and CSF data. 
Q Albumin 
In the present study the elevated Q albumin, which may represent a disturbed BBB 
function, showed no significant decrease after MP treatment. Others too have reported no 
statistical difference (Warren et al, 1986; Barkhof et al., 1992). This is not in accor­
dance with radiological studies (contrast-enhanced CT and gadolinium-DTPA enhanced 
MRI) which demonstrated an improved BBB integrity after methylprednisolone (Troiano 
et al, 1984; Barkhof et al., 1991). A possible explanation for this is that the molecular 
weight of albumin (60 kDa) and for example gadolinium-DTPA (550 Da) is quite 
different as might their routes of transport across the BBB be. Therefore both methods, 
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which may represent BBB function, probably are not measuring the same aspect of the 
BBB. 
CSF mononuclear cells 
In this study, after treatment, there was a significant drop in CSF mononuclear cells for 
the relapsing remitting (RR) and the combined (CP+RR) disease course group but not for 
the chronic progressive (CP) MS group. No correlation was found with the clinical 
scoring (EDSS). Baumhefner et al. (1989), Compston et al. (1987) and Trotter et al. 
(1980) did not find such changes, but their doses and total MP amounts (1000 mg MP 
intravenously for 3 days and 500 mg MP for 5 days) were much lower than our regimen. 
It is possible that the dose of 10 days 1000 mg MP may produce a stronger and signifi-
cant reduction in CSF mononuclear cells, indicating a stronger effect on inflammatory 
activity than lower doses. 
lgG parameters (CSF IgG, IgG index, intrathecal lgG synthesis) 
In the total MS group all three IgG parameters decreased significantly after MP treatment. 
IgG index decreased statistically significant only in the RR group. Decrease in intrathecal 
IgG synthesis after MP treatment is reported by several authors and is one of the most 
consistent findings about effects of MP on CSF parameters in both relapsing-remitting and 
chronic progressive MS (Durelli et al., 1986; Tourtellotte et al., 1980; Tourtellotte et al., 
1982; Baumhefner et al, 1989; Trotter and Garvey, 1980). In agreement with these 
studies we observed a significant reduction in intrathecal IgG synthesis in all 3 disease 
course groups of MS. 
IgM parameters (CSF IgM, IgM index, intrathecal IgM synthesis) 
We found a trend towards a significant higher intrathecal IgM synthesis and significant 
higher CSF IgM in relapsing MS versus chronic progressive or the combined (CP+RR) 
disease course. Probably due to higher pre-treatment levels only in the relapsing MS 
group there was a significant decrease in CSF IgM, IgM index and intrathecal IgM 
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synthesis after MP treatment. IgM parameters and EDSS were not significantly related to 
each other. Recently several studies about IgM in MS have been published. Sharief and 
Thompson (1991) detected intrathecal production of IgM (IgM oligoclonal bands in CSF 
and calculation of IgM index) in 55% of MS patients (n = 150) which was found to 
correlate with disease activity defined as a recent relapse as well as the total number of 
relapses. They concluded that intrathecal IgM synthesis as detected by CSF oligoclonal 
IgM bands is an useful parameter in monitoring disease activity in MS. Oligoclonal 
banding of IgM was found to be more specific for active disease than IgM index or the 
total CSF IgM amount. In an other study, Sharief and Thompson (1989) established that 
CSF oligoclonal IgM is an indicator of recent immunological stimulation. We found a 
relation between IgM and disease activity, with a trend towards a higher intrathecal IgM 
synthesis and significantly higher CSF IgM in the relapsing MS group. Possibly the 
detection of CSF IgM abnormalities by an oligoclonal IgM method is more sensitive than 
the IgM index or calculated IgM synthesis. 
Iso-electric focusing (IEF) 
After MP administration we found a significant drop in the number of oligoclonal bands 
(OB) on IEF in the whole MS group depending most on the decrease in the CP and RR 
disease course group. In 10 patients oligoclonal banding disappeared completely; 5 
patients had a RR disease course, 3 a CP course, and 2 a combined (CP+RR) disease 
course. No correlation was found with the EDSS. This disappearance of oligoclonal 
banding pattern is reported in a small number of MP treated MS patients (Durelli et al., 
1986; Trotter and Garvey, 1980). Baumhefner et al. (1989) observed no significant 
changes. For determination of the IEF before and after MP treatment we have applied a 
standardized amount of protein and not a constant IgG amount in concentrated CSF. 
Because we found significantly lower CSF IgG levels after MP treatment the possibility 
occurs that faint bands before treatment are invisible after treatment. Anyhow in our 
opinion the significant difference of the number of oligoclonal bands between pre and post 
treatment can not be completely elucidated by the used method. In accordance with 
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Tourtellotte et al. (1980), Durelli et al. (1986) sustained the hypothesis of a steroid-
resistent colony of IgG synthesizing immunocytes within the CNS (clones of B-cells) 
because of the resistance of oligoclonal banding (OB). Our data suggest that probably the 
disease course, the dose and route of MP administration are important for the effects of 
MP on the decrease and disappearance of oligoclonal banding pattern after MP treatment. 
CSF myelin basic protein (MB?) 
CSF MBP level was significantly different in the 3 disease course groups of MS. In the 
RR and the combined (CP+RR) MS group the levels were higher than in the CP group. 
In the relapsing MS group before treatment we found a positive trend between CSF MBP 
and clinical scoring (EDSS) and a significant correlation between their changes following 
MP treatment. Elevated levels of CSF MBP have been found in MS patients with active 
disease (Cohen et al., 1976; Cohen et al., 1980; Warren and Catz, 1985; Whitaker et al., 
1980; Whitaker, 1984) and seem to correspond with disease activity. In a study of 
Martin-Mondière et al. (1987) MBP was not detected in any MS patient with inactive or 
slowly progressive disease nor in any patient during exacerbations with only recurrence of 
old signs or symptoms. Thompson et al. (198S) found a significant correlation between 
CSF MBP and relapse severity in MS patients seen within 4 weeks of the onset of 
symptoms. Recently Barkhof et al. (1992) found a significant correlation between CSF 
MBP, EDSS, and the number of gadolinium enhancing lesions by MRI in relapsing MS 
patients. Using gadolinium-enhanced MRI Thompson et al. (1991) found significantly 
more enhancing lesions in the group of secondary progressive (compare CP+RR) MS 
than in the primary progressive group (CP) which may indicate a difference in 
inflammatory disease activity. These two studies demonstrate that both parameters, CSF 
MBP and the number of enhancing lesions by gadolinium-enhanced MRI, seem to 
correspond with disease activity in MS. 
In our study a significant drop in CSF MBP levels after MP treatment was demonstrated. 
Warren and Catz (1985), Warren et al. (1986) and Warren et al. (1987) found in 
exacerbating MS patients a significant drop in CSF MBP after MP treatment (160 mg/day 
36 
Methylprednisolone/CSF analysis in MS 
(160 mg/day or 2 g/day for 10 days) in contrast to ACTH treatment (60 units/day 
intravenously for 10 days). MS patients with progressive disease showed relatively insig-
nificant changes in MBP. Our results confirm those findings with significant decreases in 
the RR and CP+RR MS group and not in the CP group. All these results from different 
studies indicate that CSF MBP might be a good indicator of disease activity especially in 
relapsing MS patients. 
Correlations between CSF parameters before and following MP treatment 
Before and after MP treatment CSF mononuclear cells were significantly correlated with 
MBP, IgG index and intrathecal IgG synthesis. There was no significant correlation 
between MBP and IgG parameters. This is in accordance with findings of Warren and 
Catz (1985) and Lamers et al. (1988) who also found no correlation between CSF MBP 
and CSF IgG measurements suggesting that demyelination and local IgG activity are not 
related. The only significant relationship before and after MP treatment between MBP and 
immunoglobulines was MBP and IgM index, indicating first that demyelination (stage III) 
occurs at the time of IgM production (stage II) and second that the effect of MP treatment 
is accompanied by a correlative decrease of myelin breakdown (expressed by decrease of 
MBP) and decrease of IgM production. This suggests that MP actually interferes with the 
inflammatory process of demyelination. After MP treatment we found a significant 
reduction in CSF mononuclear cells (stage II). This may implicate a reduction in the 
number of B-lymphocytes producing immunoglobulines in the CNS compartment. 
In summary CSF MBP may be a good parameter for disease activity and also in 
evaluation of therapy, especially in MS patients with relapsing disease course. CSF MBP 
seems to be related with intrathecal IgM production and not with IgG synthesis in the 
CNS. Methylprednisolone treatment reduces both parameters in a correlative way. The 
CSF MBP levels return to reference values, however IgM production does not normalize. 
This means that the immunological process of myelin breakdown is not completely 
eradicated and may continue. 
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Methylprednisolone/T-cell subsets in MS 
Introduction 
Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous 
system of unknown origin. Contradicting findings have been reported about T-cell subsets 
in the peripheral blood (PB) and cerebrospinal fluid (CSF) of active MS patients. 
Decreased CD8+ (suppressor-cytotoxic) T-cells in PB and CSF with an increase in the 
ratio CD4+/CD8+ which correlates with an increase in T-cell activation are found to be 
related to increased disease activity (Thompson, 1983; Hauser et al., 1983a; Thompson et 
al., 1985; Oger et al., 1986; Hafler et al., 1985; Zaffaroni et al., 1985). However, these 
findings could not be confirmed in other studies (Rice et al., 1984; Kuroda et al., 1985; 
Polman et al., 1987). 
High-dose intravenous methylprednisolone (MP) often results in a rapid clinical 
improvement in patients with exacerbating MS (Durelli et al., 1986; Milligan et al., 
1987), and as well as a reduction of inflammation and demyelination expressed by a 
decrease of intrathecal IgG synthesis and CSF myelin basic protein (Warren et al., 1986; 
Frequin et al., 1991). After MP, suppression of gadolinium enhancement on magnetic 
resonance imaging (MRI) of the brain is reported indicating restoration of the disturbed 
blood brain barrier (BBB), which correlates well with clinical improvement (Barkhof et 
al., 1991; Bumham et al, 1991). 
Whether MP interferes primarily with the process of demyelination or reacts non-
specifically with its mediators is not clear. MP might act by interference with cellular 
immune mechanisms. Therefore, we studied the effects of MP on lymphocytes and 
lymphocyte subpopulations in CSF and PB of MS patients. In order to determine how the 
changes (after MP) in PB Τ subsets are related to the changes in CSF, T-cell subsets were 
simultaneously studied in both compartments. 
Patients and methods 
Between 1988 and 1990 sixty-seven consecutive patients (42 women, 25 men,) with 
clinically definite (CD) or laboratory supported definite (LSD) MS (Poser et ai, 1983) 
were studied at the University Hospital Nijmegen. The mean age was 35.5 years (range 
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21-54 yrs.), and mean disease duration was 8.5 years (range 0.5-24 yrs.). All patients 
suffered a clinical deterioration and were classified according to disease course : chronic 
progressive (CP- 32 patients), relapsing-remitting (RR- 25 patients), and chronic 
progressive with relapses and remissions (CP+RR- 10 patients). A relapse was defined as 
either the onset of new symptoms and signs or a deterioration in existing symptoms and 
signs within the previous 8 weeks and lasting longer than 24 hours, without evidence of 
spontaneous improvement. CP was defined as a continuous clinical deterioration of 
neurological symptoms and signs for at least 6 months. All patients in the RR and 
CP+RR disease course groups had a relapse at the moment of entrance into the study. No 
patient had used immunosuppressant agents 6 months prior to entrance into the study. 
Patients were treated with 1000 mg methylprednisolone-acetate (MP) daily for 10 
consecutive days administered intravenously between 9:00 and 10:00 a.m. over 
approximately 15-20 minutes. No tapering dose was used after the 10 day MP course. 
Before and after MP treatment, the clinical status was scored according to Kurtzke's 
Expanded Disability Status Scale (EDSS) (Kurtzke, 1983) by a neurologist (SF) who was 
unaware of the CSF and PB findings. Progression rate was defined as the ratio of EDSS 
to disease duration. Thirteen patients (8 women, 5 men), aged 30-69 years (mean 42.1 
yrs.), with herniated lumbosacral discs served as controls. 
Immediately before and after MP treatment, PB and CSF samples were obtained 
simultaneously according to standard procedures. White blood cell count and leukocyte 
differentation were performed routinely using a Coulter Counter and May-Grunswald 
Giemsa staining. For determination of lymphocyte subpopulations, lymphocytes from 
heparinized PB were isolated by Ficol-isopaque density gradient centrifugation (1.085 
g/cm3). The remaining erythrocytes were lysed and the cells were washed twice and 
labelled according to the procedure described by Reinherz et al. (1980). The following 
monoclonal antibodies (MAB) were used: anti-CD3 (OKT3, total Τ cells), anti-CD4 
(OKT4, helper/inducer T-cells), anti-CD8 (OKT8, suppressor/cytotoxic T-cells), anti-
OKIal (activated cells, Ortho Pharmaceutical, Raritan, N.J.), and anti-CD20 (B-cells, 
Coulter clone, Lutton, Beds; England). 
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For CSF cell analysis we used a micromethod. The CSF was centrifugea (10 minutes, 
400 χ g, 20 C) and the supernatant was removed. The remaining cell suspension was 
aliquoted over Eppendorf cups. The cells were washed once with 2% bovine serum 
albumin in Tris buffered minimal essential medium. The supernatant was removed, and to 
the remaining SO μ\ cell suspension 2 μΐ MAB was added and the suspension was 
incubated for 30 min at 4 C. After two wash steps, the suspensions were incubated with 
25 μΐ goat anti-mouse fluorescene isothiocyanate conjugate (GAM/FITC). After 
incubation, the cells were washed twice and the cell pellets were fixed overnight in 100 μΐ 
1% paraformaldehyde. Then 10 μΐ ethidium bromide (10 g/ml PBS) was added for 
nuclear staining. Subsequently, the cell suspensions were cytocentrifuged and embedded 
in glycerol/NaN] (2Smg NaN3 and 10mg paraphenylene diamine in 1 ml aqua bidest and 9 
ml glycerol). For cell counting we employed a Zeiss fluorescence microscope equipped 
wih a HBO SOW mercury lamp and the filter combination BP 485/20, FT 510, LP 520, 
using an oil immersion objective 63 χ 1.30 and a pair of 8X oculars. At least 100 cells in 
duplicate were counted per monoclonal antibody. In both PB and CSF the proportion of 
lymphocytes was expressed as the percentage of the total mononuclear cell count. 
Statistics 
Differences between the three disease course groups were tested by means of the 
Kruskall-Wallis test. Data before and after MP treatment were compared by means of the 
Wilcoxon's signed rank test. Relations between PB and CSF data were calculated by 
means of Spearman's correlation coefficient. P-values of 0.05 or less (two-sided) were 
considered as statistically significant; p-values between 0.05 and 0.10 were considered as 
trends. 
Results 
T-cell subsets in PB and CSF of 67 MS patients before and after MP treatment (Table 1). 
Before MP treatment, CSF Bl-cells were significantly higher (p < 0.005), PB CD4+ T-
cells and PB CD4+/CD8+ ratio levels were significantly lower (p < 0.05) in MS 
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patients than in controls. The percentage of CSF CD4+ T-cells in MS patients tended to 
be higher compared with controls (p = 0.072) (Figure 1). In the MS patients, the 
percentage of CD4+ T-cells in the CSF was significantly higher than in the PB (ρ = 
0.0001) (not in the table). After MP treatment, a significant increase was found in the 
CSF CD8+ cells (p = 0.0009) resulting in a decrease of the CSF CD4+/CD8+ ratio, 
and a decrease in PB CD8+ T-cells (p = 0.0006) resulting in an increase of the PB 
CD4+/CD8+ ratio (Figure 2). 
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Figure 1. Mean percentages (+/-1 standard deviation) ofCD4+ T-cells in the CSF and 
PB of 67 MS patients before and after high-dose intravenous MP, according to the course 
of the disease, and in 13 controls. CP= chronic progressive; RR= relapsing-remitting; 
CP+RR= combination. 
Spearman's correlation coefficients between the PB and CSF variables before MP 
treatment are shown in Table 2. There is a clear positive correlation between each 
corresponding T-cell subset percentage in the CSF and PB. Table 3 shows the correlation 
coefficients between the total number of CSF mononuclear cells and T-cell subsets in the 
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PB and CSF. A high cell count of CSF mononuclear cells correlates with higher 
percentages of CSF CD3+ and CD4+ T-cells and lower CSF CD8+ T-cell percentages, 
and subsequently higher CSF CD4+/CD8+ ratios. 
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Figure 2. Mean percentages (+/-1 standard deviation) ofCD8+ T-cells in the CSF and 
PB of 67 MS patients before and after high-dose intravenous MP, according to the course 
of the disease, and in 13 controls. 
Relation between clinical variables and T-cell subsets in PB and CSF before and after MP 
treatment. 
The EDSS-score decreased significantly after MP for the entire MS group and in all 
subgroups (Tables 1 and 4). The CSF mononuclear cell counts were significantly higher 
in the patients with a RR or CP+RR disease course than in the patients with a CP course 
(p < 0.0S). The CSF mononuclear cell counts were negatively correlated with age (r = 
-0.44; ρ < 0.001) and disease duration (r = -0.32; ρ < 0.01). None of the other cellular 
variables were significantly correlated with the course or duration of the disease, age, 
EDSS, or rate of progression of the disease. The values of the different PB and CSF 
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variables for the various courses of disease are shown in Table 4. The changes of the T-
cell subset percentages after MP were independent of the changes in the EDSS and not 
significantly correlated with the various courses and rate of progression of the disease 
(not in the table). 
Methylprednisolone/T-cell subsets in MS 
Table 1. EDSS, peripheral blood (PB) and cerebrospinal fluid (CSF) Τ subsets in 67 Multiple 
Sclerosis (MS) patients before and after treatment with high-dose intravenous methylprednisolone 
(MP) and in 13 controls with lumbosacral disk herniation. 
EDSS 
PB leukocytes 
lymphocytes 
CD3 + 
CD4+ 
CD8 + 
CD4+/CD8+ 
Ial + 
Bl 
CSF mononu­
clear cells 
CD3 + 
CD4+ 
CD8+ 
CD4+/CD8 + 
Ial + 
Bl 
Controls 
-
7.2 (2.8) 
29.9 (5.0) 
66.6 (7.3) 
46.0 (8.9) 
20.3 (4.5) 
2.4 (0.7) 
7.8 (4.4) 
5.5 (2.9) 
2.8 (2.4) 
76.8 (6.1) 
49.8 (9.7) 
18.8 (5.9) 
2.7(1.1) 
7.3 (2.2) 
2.4 (3.2) 
Unit 
-
χ lO'/I 
% 
% 
% 
% 
-
% 
% 
/3mm3 
% 
% 
% 
-
% 
% 
MS Patients 
Before MP 
4.3 
6.3 (2.3) 
27.5 (8.8) 
61.3(11.8) 
37.3 (12.7)· 
23.8 (9.1) 
1.9(1.1)' 
9.1 (5.8) 
5.2 (4.1) 
19.6 (33.7)*~ 
79.2(11.2) 
55.7 (13.7/ 
21.9 (7.6) 
2.9(1.4) 
9.1 (5.5) 
5.6 (4.3Γ 
AfterMP 
3.4 
10.4 (4.5)** 
19.1 (10.3)-* 
59.9(11.0)" 
37.1 (13.6)· 
21.0 (7.4) 
2.1 (1.3) 
10.7 (6.2) 
5.9 (3.6) 
11.1 (15.6)*** 
78.7 (10.4) 
51.6(11.7) 
25.3 (9.0)· 
2.3 (1.0) 
12.8 (8.1)· 
7.8 (5.8)~ 
P-value 
0.001 
0.0001 
0.0001 
ns 
ns 
0.0006 
ns 
ns 
ns 
0.0005 
ns 
ns 
0.0009 
0.0001 
0.0075 
ns 
Legend: Mean levels with one standard deviation are reported. Wilcoxon's rank sum test; ' =p 
< 0.10; * =p < 0.05; ** =p < 0.01; *** =p < 0.001 tested against the controls (second 
column); without annotation corresponds to values which are not significantly different with 
respect to the controls. In the last column the p-values indicate the significance between the levels 
before and after treatment. EDSS= Expanded Disability Status Scale; ns= not significant. The 
percentages of lai + and Bl cells refer to the percentages of mononuclear cells in the PB and 
CSF, respectively. 
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Table 2. Spearman correlation coefficients between the percentages of T-cell subsets in the PB 
and CSF of 67 MS patients before MP treatment. 
CSF 
CD3 + CD4+ CD8+ CD4+/CD8 + Ial + Bl 
явея 
Ш А Щ І 0.28 
M s L . .„. 
PB 
CD3 + 
CD4+ 
CD8 + 
CD4+/CD8 + 
Ial + 
Bl 
ns 
0.36-
ns 
ns 
ns 
ns 
œ*km » \ s á ^ 
ns 
ns 
ns 
0.24' 
ns 
ns 
f^Mfel ns 
-0.32* 
ns 
ns 
ns 
ns 
ns 
ns 
ns 
ns 
ns 
ns 
ns 
ns 
Ш&М 0.28· 
0.50~ ^ Ü r l 1 
Legend: ns= not significant; * =p < 0.05; ** =p < 0.01; *** =p < 0.001; ****= 
0.0001. 
Ρ < 
Table 3. Spearman correlation coefficients between the CSF total number of mononuclear cells 
with the percentages of T-cell subsets in the PB and CSF of 67 MS patients before MP treatment. 
i i i j i i i^mi^Mjj i imi 
*cerí 
A^r&tèg 
'Jtì CD3+ CD4+ CD8+ CD4+/CD8 + Ial-f- BI 
PB 
CSF 
ns 
0.40" 
0.25* 
0.47*" 
ns 
-0.33* 
0.25* 
0.46*" 
ns 
ns 
ns 
ns 
Legend: See Table 2. 
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Discussion 
The most striking finding in this study is the different effect of MP on CD8+ T-cells in 
PB and CSF. The percentage of CD8+ T-cells (with corresponding changes in the 
CD4+/CD8+ ratios) decreases in the PB and increases in the CSF concomitantly, 
independent of the course of disease. The decrease of CD8+ T-cells in the PB and 
increase in the CSF may represent migration of these CD8+ T-cells into the central 
nervous system (Hafler and Weiner, 1987). Although most cells in the CSF are of 
hematogenous origin (Tourtellotte and Ma, 1978), both selective migration of cells 
through the blood brain barrier and intrathecal expansion could contribute to different Τ 
subsets in PB and in CSF (Noronha et al, 1980; Vandenbark et al, 1985). Weiner et al. 
(1984) proposed that (chronic) active lesions in the CNS of MS patients could be the 
sequestration site of the CD8+ T-cells. Hayashi et al (1988) and McCallum et al. (1987) 
found also a predominance of CD8+ lymphocytes in the perivascular and parenchymal 
compartments of MS lesions. Raine (1988) stated that the strongest evidence for cessation 
or reversal of the immunological events in the resolving MS lesion lies in finding fewer 
CD4+ T-cells in the parenchyma and an increased presence of CD8+ T-lymphocytes, 
particularly around blood vessels. Estes et al. (1990) indicated that both CD4+ and 
CD8+ lymphocytes are present in active MS lesions. 
Data on the effects of corticosteroids on T-cell subpopulation in MS patients are often 
conflicting. Compston et al (1987) reported no statistically significant effects on OKT4 
and OKT8 cells in the PB of MS patients after MP treatment. Salinaggi et al. (1991) 
found increased numbers of CD3+ and CD4+ T-cells, with an increased CD4+/CD8+ 
ratio, in the PB of MS patients during dexamethasone treatment followed by a decrease 1 
and 2 weeks after the end of the treatment. Kirk and Compston (1990) reported no 
alterations in CD4+ and CD8+ T-cells, or activated lymphocytes in the PB in 25 MS 
patients who were treated with 0.5 g methylprednisolone intravenously daily for 5 days. 
CSF analysis was not performed in these three studies. 
In the present study we found a significantly lower percentage of CD4+ T-cells in the PB 
of MS patients, especially in the CP group. In MS patients, the percentage of CD4+ T-
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cells in the CSF was significantly higher than in the PB and the CSF CD4+ T-cell 
percentage tended to be higher than that of controls. These findings are in accordance 
with the study of Scolozzi et al. (1992). In our study, normal percentages for CD8+ T-
cells in the PB and CSF of the MS patients, independent of the course of the disease, 
were obtained. Other studies have revealed a loss of circulating CD8+ (suppressor/cyto-
toxic) T-cells in PB or CSF in active or chronic progressive MS with subsequently higher 
CD4+/CD8+ ratios (Zaffaroni et al, 1985; Reinherz et al., 1980; Antel et al, 1979; 
Hauser et al, 1983b; Paty et al, 1983; Matsui et al, 1988; Uitdehaag et al, 1989). 
However, unchanged levels of CD8+ T-cells have been reported by others, both in PB or 
CSF (Kuroda and Shibsaki, 1985; Polman et al, 1987). One reason for the conflicting 
results may be that different methods (staining by fluorescent or enzyme-linked antibo-
dies, type of antibody used, enumeration of the cells by microscopical evaluation or by 
flow cytometry) are used for determine the PB and CSF cells, usually requiring high CSF 
cell counts. We used a micro fluorescence method with the advantage of performing 
lymphocyte-subset analysis in the CSF in the abscence of pleocytosis. 
Comparing the different disease courses in MS, we found a significant relationship 
between disease course and CSF pleocytosis: MS patients in acute relapse (RR or 
CP+RR) had higher CSF cell counts than patients with chronic progressive (CP) disease. 
This is consistent with previous reports (Scolozzi et al, 1992; Olsson and Link, 1973; 
Frequin et al, 1992). No relationship could be found between the percentages of T-cell 
subsets in CSF or PB with the different courses of disease or other clinical variables 
(EDSS, disease duration, progression rate). 
The CSF pleocytosis in the MS patients in our study consisted predominantly of CD3+ 
T-cells, whose percentage is significantly higher in CSF than in PB. This is in agreement 
with previous studies (Kam-Hansen, 1980; Fredrikson et al, 1989). Furthermore, the 
CSF pleocytosis is positively correlated with the percentage CSF CD4+ T-cells and 
negatively correlated with the percentage CSF CD8+ T-cells. A correlation of highei 
CSF mononuclear cell counts with a decreased percentage of suppressor/cytotoxic T-cells 
in the CSF has been found also by others (Hauser et al., 1983a; Hommes and Brinkman, 
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1984). Vanderbark et al. (1985) stated that a selective increase of CD4+ T-lymphocytes 
account for increased cellularity in the CSF. 
The percentage of B-lymphocytes in the CSF of MS patients was significantly higher than 
in controls; this was not found in PB. Prior studies, using different methodologies, have 
found either higher or lower percentages of B-cells (Coyle et al., 1980; Henriksson et al., 
1981). The lal antigen, usually present on monocytes, B-lymphocytes, and some activated 
CD4+ T-cells (Reinherz et al, 1980), was found to be normal in PB and CSF. 
Similarly, Hauser et al. (1983a) have not found an increased percentages of lai + cells in 
the PB and CSF of MS patients. 
After treatment with intravenous 1000 mg MP daily for consecutive 10 days, we found a 
leukocytosis in the PB, a decrease in the lymphocyte percentage, and unchanged PB 
CD3+ and CD4+ T-cell percentages. The reduction of the percentage of lymphocytes in 
the PB after MP is probably due to a redistribution of lymphocytes from intravascular 
into peripheral compartments rather than due to killing of cells (Fauci and Dale, 1974; 
Schuyler et al, 1984; Fauci, 1987). 
In conclusion, our findings suggest that in MS patients MP increases the Τ 
suppressor/cytotoxic subset in the CSF, possibly through migration of CD8+ T-cells 
from the PB compartment into the CNS. So, MP might have a selective and dissociative 
effect on CD8+ T-cells in the PB and CSF in MS and MP might affect the inflammatory 
process of demyelination by interference with T-suppressor/cytotoxic cells. 
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DECREASED VITAMIN B u AND FOLATE LEVELS IN CEREBROSPINAL 
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Methylprednisolone and vitamin B12/folate in MS 
Introduction 
Recently renewed attention has been drawn to the presence of low or decreased vitamin 
B,2/ folate levels (Nijst et ai, 1990; Reynolds et al., 1991) and macrocytosis (Crellin et 
al., 1990) in patients with multiple sclerosis (MS). Deficiency of vitamin B12 and folate 
are associated with cerebral demyelination and subacute combined degeneration of the 
spinal cord (SACD) (Chanarin, 1979). The role of vitamin BJ2 and folate metabolism in 
myelin formation and in the mechanism of inflammatory and non-inflammatory 
demyelination is not well understood. It has been suggested that a defective metabolism of 
the methyl-transfer pathway with a reduced supply of methyl-groups and low S-adenosyl-
methionine may be a cause of demyelination (Scott et al., 1981; Surtees et al., 1991). In 
children with HIV infection it has been suggested that the neurological complications 
(demyelination, SACD, vacuolar myelopathy) are due to a defective methylation caused 
by inhibition of the folate metabolism resulting from chronic stimulation of the 
macrophage system (Smith et al., 1987; Surtees et al., 1990). 
In MS corticosteroids, especially intravenously administered methylprednisolone (MP), 
can stop or reduce the inflammatory process of demyelination, which is expressed by a 
beneficial clinical effect (Durelli et al., 1986), lowering of the intrathecal IgG production 
(Warren et al., 1987) and of the cerebrospinal fluid (CSF) myelin basic protein (MBP) 
concentration (Warren et al., 1987; Frequin et al., 1991). In MS patients a reduction of 
gadolinium-DTPA enhanced lesions on MRI is found after high-dose intravenous MP 
(Barkhof et al, 1991), indicating restoration of the disturbed blood-brain-barrier and 
decrease of inflammation. 
We studied the levels of vitamin B12 and folate in serum and CSF in MS patients. The 
purpose of this study was to investigate the influence of corticosteroids on the vitamin B,2 
and folate levels in MS patients. 
Patients and methods 
Twenty-one patients (IS women, 6 men) with clinical or laboratory supported definite MS 
(Poser et al., 1983) were treated for a symptomatic neurological deterioration. Mean age 
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and disease duration was 37 year (range 23-54 year) and 9 year (range 1-25 year) 
respectively. Ten patients had a chronic progressive disease course, 8 a relapsing-
remitting, and 3 a combined disease course. None of the patients had used 
immunosuppressive agents for at least 6 months. Nine patients had never 
immunosuppressive medication before; 8 patients had been treated once with 
cyclophosphamide or azathioprine and 4 with oral corticosteroids. None of the patients 
used vitamin B12 or folate, and none used trimethoprim, Bactrimel" (trimethoprim with 
Sulfamethoxazol), or anti-convulsants. 
In this study the patients were treated with daily 1000 mg MP-succinate administered 
intravenously for 10 days. No tapering dose was used. Serious side effects did not occur. 
Just before and after 10 days of MP treatment CSF and serum samples were taken 
simultaneously. For measuring the clinical scoring the Kurtzke's Expanded Disability 
Status Scale (EDSS) was used (Kurtzke, 1983). 
Vitamin B12 and folate levels in CSF and serum were measured according the instructions 
of the manufacturer using the Quantaphase B12/folate radio immuno assay (Biorad 
1911002, California, USA) with the following exceptions. CSF samples (4 ml) were 
evaporated until dryness in a Vortex evaporaton/Buchler Instruments Ine, New York, 
USA and subsequently taken up in 0.5 ml of the Biorad zero standard. In the assay only 
50 μΐ instead of 100 μΐ of the microbead reagent were used, both for serum and CSF 
determinations. After a 1 hour incubation period and subsequent centrifugation, we added 
a washing step with 1 ml saline. Samples were always determined in duplicate. Two 
additional standards (18 and 37 pmol/1) were used for the low vitamin B12 range. For the 
determination of CSF folate the sample was diluted with the Bio-rad zero standard (50% 
v/v). 
The reference levels for vitamin B12 and folate in serum and CSF have been determined in 
a group of 157 patients with a neurological disease from which no association with low 
vitamin B12 or low folate levels is known (Nijst et al., 1990). 
For statistical analysis the two-tailed sign test was used. P-values below 0.05 were 
considered significant. Four patients had incomplete data. For 1 patient only folate levels 
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were available before and after MP treatment; 2 other patients data on CSF vitamin B l 2 
before and after MP treatment were missing, and 1 patient data on serum vitamin B,2 and 
serum folate before and after MP treatment. 
Results 
Before MP treatment mean EDSS was 3.6 (range 2.0-8.0), after treatment 3.0 (range 1.0-
7.0). Thirteen patients had a lower EDSS by 1.0 point or more; 8 patients remained 
clinically unchanged. Gender, age, disease duration, and EDSS were not statistically 
significant related with CSF or serum vitamin B,2 and folate levels. Progression rate, 
defined as the ratio between EDSS and disease duration, was significantly (p=0.0084) 
negative correlated with serum vitamin B12 (r=-0.59). Spearman correlation coefficient 
between serum and CSF vitamin B12 levels was 0.46 (p=0.0641); between serum and 
CSF folate levels 0.58 (p=0.0068). 
Table 1. Cerebrospinal fluid (CSF) and serum levels of vitamin B12 and folate in 21 MS patients 
before and after treatment with high-dose intravenous methylprednisolone (MP). 
References Before MP After MP ρ Value 
Vitamin B
u
 (pmol/1) 
CSF N=18 
Serum N=19 
Folate (nmol/l) 
CSF N=21 
Serum N=20 
8.7 (2.1-22.9) 7.9 (1.5-21.0) 7.1 (1.5-18.1) 0.0127 
284 (142-541) 289 (89-444) 267 (52-612) ns 
24.8(14.4-42.1) 26.0(9.041.6) 20.6(4.0-33.2) 0.0004 
10.4(5.5-19.1) 10.3(4.1-18.5) 8.1(4.2-12.4) 0.0044 
Legend: Median and 5%-95% ranges are mentioned. Statistical analysis (sign test) was performed 
between the levels before and after MP treatment. ns= not significant. 
The results of CSF and serum vitamin B12 and folate levels before and after MP treatment 
are shown in Table 1. The individual levels and changes in CSF and serum vitamin B,2 
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and folate are shown in Figures la-b and 2a-b. In one patient an increase of CSF levels of 
vitamin B12 and folate was noted shortly after treatment and again a reduction after a 
second MP treatment (Figure 3). 
Before MP treatment CSF and serum median levels of vitamin B t2 and folate were 
statistically not different from the reference median levels. After MP treatment a 
significant decrease was demonstrated in the CSF and serum levels of folate and in the 
CSF level of vitamin B12. The decrease in serum vitamin B12 was not statistically 
significant. The observed changes in CSF and serum vitamin concentrations were not 
dependent of the clinical parameters gender, age, disease duration, and progression rate 
or with the changes in EDSS after MP treatment. After treatment all median levels were 
below the reference medians; only this was statistically significant (p<0.01) for the level 
of serum folate. 
CSF vitamin B, 
Before After 
MP Treatment 
700 
600 
500 
400 
300 
200 
pmol/l 
Serum vitamin B12 
100 r-
Before After 
MP Treatment 3  reat Ь 
Figure 1. CSF (a) and serum (b) vitamin B
n
 levels before and after high-dose 
intravenous methylprednisolone ßiP). 
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Figure 2. CSF (a) and serum (b) folate levels before and after high-dose intravenous 
methylprednisolone. 
Discussion 
From this study it is suggested that high dose MP treatment in MS patients reduces 
vitamin B12 and folate levels in CSF and folate levels in serum. This could, however, lead 
to questions concerning the findings of low or reduced vitamin B12 levels in serum and/or 
CSF of MS patients (Nijst et al, 1990; Reynolds et al., 1991) as this could be explained 
by previous and perhaps anamnestically undiscovered corticosteroid treatments in these 
patients. Nijst et al. (1990) found lower median CSF vitamin B12 concentrations (6.9 
pmol/1; in our study 7.1 pmol/1 after MP) in a group of 58 MS patients, but it is not clear 
if these patients received corticosteroids. In the study of Reynolds et al. (1991) on 10 
patients with MS and vitamin B12 deficiency, it is not mentioned if they were treated with 
corticosteroids or not. 
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Before MP treatment there was a positive correlation between the serum and CSF levels 
for vitamin B,7 and folate. Lazar and Carmel (1981) found no correlation between vitamin 
B|2 levels in the serum and CSF which is in contrast to the finding of Nijst et al. (1990), 
who showed a significant positive correlation (Pearson correlation coefficient 0.66) 
between serum and CSF vitamin B,2 levels in MS patients. 
CSF Folate (nmol/l) CSF Vit B12 (pmol/l) 
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Figure 3. CSF vitamin Bl2 and folate levels before and after the first and second course 
with high-dose intravenous methylprednisolone (MP) in one MS patients. 
After corticosteroid treatment in MS patients lowering of vitamin B12 and folate levels is 
not expected because there is no known biochemical relationship between corticosteroids 
and vitamin B12/ folate metabolism. In line with the folate and vitamin B,2 dependent 
methyltransfer theory about myelination (Scott et al., 1981; Surtees et ai, 1990; Surtees 
et al., 1991) one could speculate about the results of this study. An explanation for the 
phenomenon of lower vitamin B,2 and folate levels after MP may be that at the same time 
as the decrease of inflammation and demyelination into the central nervous system occurs 
as a result of MP (Warren et al., 1987; Frequin et al., 1991), repair of myelin and 
formation of new myelin (remyelination) by the oligodendrocytes begins with an increased 
demand for the available vitamin B12/folate and lower values of vitamin B12 and folate 
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ifterwards. 
It would be of interest to know if these findings could be repeated in other types of 
patients with demyelinating disease receiving high dose corticosteroid treatment, or 
whether this phenomenon occurs mainly in the CSF and serum of MS patients because of 
:hanges in the cerebral metabolism caused by such treatment as mentioned above. If such 
findings could be replicated in other types of patients with demyelinating disease then the 
relationship between vitamin B12/folate metabolism and myelination seems to be a more 
»usai one and further study will be required to elucidate the nature of this association. 
Of particular interest is the observation of a "compartmental effect" of MP on vitamin B12 
with a significant lowering in the CSF and not in the serum. Gadolinium-enhanced MRI 
studies of the brain in MS patients have shown that corticosteroids, especially high- dose 
MP, improve Blood Brain Barrier (BBB) integrity (Barkhof et ai, 1991), possibly by 
decreasing transendothelial vesicular transport (Bumham et al., 1991); therefore it is 
possible that MP blocks the transport of vitamin B12 to the CSF. In contrast to vitamin B n 
both CSF and serum levels for folate are decreased after MP. An explanation could be 
that the effects of corticosteroids on the transport-mechanisms through the BBB and 
blood-CSF barrier might be different for vitamin B12 (facilitated diffusion) and folate 
(active transport at the choroid plexus). 
We agree with Reynolds et al. (1991), that the association of MS and low vitamin B12 is 
likely to be more than coincidental and should be determined. A possibility is the use of 
corticosteroids which we found to lower the vitamin B12 and folate levels in MS. 
Otherwise a more causal relationship is suggested because vitamin Bl2 and folate 
metabolism seems to be essential in the formation of myelin and remyelination (Smith ei 
al., 1987). We found a statistically significant negative correlation between vitamin B12 in 
serum and disease activity which is in agreement with a more causal relationship between 
vitamin B,2 and myelin breakdown/formation. 
Finally, if it is true that corticosteroids decreases vitamin B,2 and folate levels in MS 
patients, it might be desirable to administer these patients vitamins when they are treated 
with corticosteroids. 
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CHAPTER 5 
RELAPSING-REMITTING MULTIPLE SCLEROSIS: SEQUENTIAL ENHANCED 
MR IMAGING VS CLINICAL FINDINGS IN DETERMINING 
DISEASE ACTIVITY 
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Enhanced MRI in relapsing MS 
Introduction 
MR imaging of the brain frequently shows new lesions in patients with MS who do not have 
accompanying clinical signs and symptoms (Isaac et al., 1988; Koopmans et al., 1989; 
Willoughby et al., 1989). MR imaging thus seems to be a sensitive marker for disease activity 
in MS, which makes it potentially useful for monitoring disease activity (e.g. in conducting 
pilot studies of putative therapeutic regimens). It has been suggested that the most effective 
MR imaging parameter to assess disease activity in MS is Gd-enhancement (Miller et al., 
1991; Thompson et al., 1991 and 1992; Harris et al., 1991). Gd-enhancement is correlated 
with disease activity in MS (Barkhof et al., 1991; Miller et al., 1988; Grossman et al., 1988), 
and in experimental allergic encephalitis, a disease model that resembles MS (Hawkins et al., 
1991). 
Little is known about the value of using contrast-enhanced MR imaging to assess disease 
activity in patients with MS. Such information is important for estimating the number of 
patients needed to demonstrate a certain treatment effect of a given drug. Disease activity 
shown on MR appears to vary widely with respect to different clinical courses of the disease. 
Patients with SP disease show new lesions far more frequently than patients with primary 
progressive disease do (Thompson et al., 1991). Patients with early RR disease show more 
lesions than patients with benign disease do (Thompson et ál., 1992), and a similar number 
of lesions to that in patients with SP disease. Also within well-defined populations, however, 
variations of MR disease activity in individual patients and among patients in a group of 
patients are substantial. 
Monitoring disease activity in the group of RR MS patients will become increasingly 
important as new and safe therapies are developed to prevent new disease activity (Rudge, 
1992). So far, only two sequential MR studies of RR MS that used contrast-enhancement have 
been reported (Harris et ál., 1991; Thompson et al., 1992). We sequentially studied seven 
patients with early RR MS to determine the value of Gd-enhanced MR images in assessing 
disease activity in this subgroup of patients, and to compare MR imaging and clinical findings 
for this purpose. 
77 
Subjects and methods 
Seven patients with RR definite MS according to current diagnostic criteria (Poser et al., 
1983), were prospectively examined at monthly intervals for 4-12 months. Patients were 
evaluated clinically and were scanned with a standard MR imaging protocol, including 
gadopentetate dimeglumine enhancement. None of the patients was treated with steroids or 
other immunosuppressants in the six months before or during the study period, as steroid-
medication suppresses contrast-enhancement (Barkhof et al., 1991). 
The mean age was 24 years (range, 19-36 years), and the mean disease duration was 2.7 years 
(range, 0.6-5.0 years). The median clinical disability upon entry, assessed by means of the 
commonly used EDSS (Kurtzke, 1983) was l.S (range, 1.0-2.0). All patients had oligoclonal 
bands in their CSF on isoelectric focusing, indicating selective IgG antibody production. The 
initial presenting symptom had been optic neuritis in three patients, sensory symptoms in 
three, and internuclear ophthalmoplegia in one. A relapse was denned as any clinical 
deterioration lasting more than 24 hr, not related to a concurrent illness. 
One patient discontinued the study for personal reasons after four imaging sessions. During 
the study, three patients suffered from a total of five clinical relapses. These clinical relapses 
led to a change in the EDSS score of 1.0 or more in three relapses. All patients recovered 
spontaneously. At the last imaging examination, one patient had very mild sensory symptoms, 
which progressed and led to treatment with methylprednisolone 1 month later. The EDSS 
scores at the end of the study were identical to the entry scores for all patients. 
MR imaging was performed on a 0.6-T machine (Technicare, Solon, Ohio) with a standard 
head coil. The same imaging protocol was used throughout the study. Identical slice 
repositioning was achieved by means of unenhanced images in three consecutive planes 
(transverse, oblique/coronal, and oblique/sagittal), thereby correcting for differences in the 
patient's position according to internal landmarks (Figure 1). From the midsagittal image, 
double oblique two-dimensional axial series were planned. T2-weighted spin-echo (SE) images 
were obtained with 2755/60,120(reduced bandwidth)/2 (TR/TE/excitatìons). Nineteen slices 
with an in-plane resolution of 1.0 χ 1.3 mm, and a slice thickness of 5 mm were obtained 
with a gap of 1.25 mm, resulting in a Ζ range of 11.75 cm. The Ζ center was aligned with 
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the caudal border of the splenium of the corpus callosum (Figure 1С). 
Gadopentetate dimeglumine (Magnevist, Schering AG, Berlin) was administered IV as a bolus 
in a dose of 0.2 mmol/kg (recommended dose in Europe 0.1-0.2 mmol/kg), with the patient 
remaining in the same position in the head coil. A postinjection flush of 10 ml of normal 
saline was given. T,-weighted SE images (2 series of 9 slices) were then obtained with 
400/28(normal bandwidth)/4, done in exactly the same way as the upper unenhanced slices 
were done (identical spatial resolution), starting 5-10 min after Gd-injection. The total 
examination time was SO min. 
The MR images were analyzed by two neuroradiologists in conference. Slice repositioning 
was evaluated for each follow-up scan and graded as good, moderate, or poor. Repositioning 
errors can result from either inaccuracy in anterior/posterior or left/right angulation or 
inaccuracy in Ζ offset. Repositioning was graded as good when there was less than half a slice 
of inaccuracy in any part of an image, as moderate when more than half a slice but less than 
a whole slice of difference occurred, and as poor if differences of more than a slice were 
encountered. An area of markedly increased signal intensity on the contrast-enhanced T,-
weighted images, not related to a physiologically enhancing structure (Killgore et al., 1986; 
Sze et al., 1989), with a diameter of 3 mm, was considered a contrast-enhancing lesion. 
Lesions were classified as directly periventricular (adjacent to the ventricular system), deep 
white matter, gray matter, junction of gray and white matter, or infratentorial. They also were 
classified as smaller or larger than S mm. On the initial T2-weighted MR images, a total lesion 
score was assessed by using a semiquantitative scoring system (Thompson et al., 1991). The 
Tj-weighted images also were evaluated as to whether enhancing lesions were shown, and 
whether they changed in appearance at follow-up. Therefore abnormalities on T2-weighted 
images were classified as clearly visible, poorly visible, or only recognizable because of prior 
knowledge of the contrast-enhanced T,-weighted images ("retrospective''). In order to exclude 
artificial changes, attributable to repositioning errors, "disappearance" of lesions was defined 
as a lesion not being visible on two consecutive scans. 
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Figure 1. Protocol to achieve identical section repositioning/or sequential axial scans. Patient 
assumes a comfortable position in magnet bore. Three consecutive pilot scans are used to 
correct for rotations along three orthogonal axes. First a tranverse unenhanced MR image 
(left) is obtained, from which the angle of (oblique) coronal image is planned (perpendicular 
to midline). Coronal MR image (middle) is then used to plan (oblique) sagittal image, along 
cerebral falx. Resulting sagittal MR image (right), which is the logical midsagittal image, is 
then used to plan (double-oblique) axial slices, angulated parallel to line connecting caudal 
border of pituitary gland and fastigium of fourth ventricle, while Ζ center is aligned with 
splenium of corpus callosum. Essentially this section-repostioning protocol uses only internal 
landmarks of brain, without any inconvenience for patient. 
Results 
MR imaging. A total of 58 monthly MR examinations was performed. The slice reposi­
tioning was graded as good in 39 (76%) of 51 follow-up scans, moderate in 11 (22%), and 
poor in one (2%). In five patients, the repositioning was good in more than 75% of the scans; 
in two patients, however, repositioning was good in less than 50% of the scans. The MR 
imaging results are displayed in Table 1. The initial T2-weighted images showed a mean total 
lesion score of 63.3 (range, 11 -129). Six of seven patients showed one or more new enhancing 
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lesions during the study. The proportion of images that showed enhancement per patient varied 
from 0%-80% (mean ± S D , 42% +31%). Fifty new contrast-enhancing lesions were seen 
in 25 (43%) of the 58 images. The Pearson correlation coefficient between the initial lesion 
load and the mean number of enhancing lesions was 0.52 (p=.23), and between the initial 
lesion load and the proportion of scans showing enhancement was .61 (p=.14). 
Table 1. Number of new Gd-enhancing lesions on monthly Τ,-weighted MR scan of the brain in 
patients with RR MS. 
Case 1 2 3 4 5 6 7 
MR findings 
Lesion load 79 11 97 129 27 50 50 
No. of new Gd-lesions/month 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
0 
0 
'1 
0 
-
-
-
-
-
-
-
-
0 
1 
0 
0 
0 
0 
0 
0 
1 
0 
0 
0 
5 
(13/10 
(6)2 
(3)2 
(2)1 
2 
'2 
0 
0 
1 
-
-
0 
3 
2 
2 
1 
1 
1 
(DO 
0 
-
-
. 
2 
'1 
1 
0 
3 
1 
0 
0 
'2 
0 
-
. 
0 
0 
0 
0 
0 
0 
0 
-
-
-
-
. 
1 
0 
0 
1 
0 
0 
-
-
-
-
-
-
Note. Initial lesion score was assessed on the unenhanced T2-weighted initial images by using a 
semiquantitative scoring system (Thompson et al., 1991), and represents the lesion-load sofar. 
Numbers in parenthesis indicate the total number of enhancing lesions (new, persistently enhancing 
and one (case 4, 8th month) reenhancing) on that month's MR image, in cases where the lesions that 
enhanced were not all new lesions. ' Indicates the timing of the clinical relapses. 
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Figures 2 and 3 show sequential images at two different levels in one patient. One contrast-
enhancing lesion was first seen on the last scan, so no follow-up was available. Most other 
lesions (n =42, 86%) were seen to enhance on only one occasion. In one patient, in total seven 
lesions were still enhancing on the first follow-up scan, two of which (4%) were still 
enhancing on a second follow-up scan. 
Figure 2. Case 3. Unenhanced image (left) shows several white matter lesions, which do not 
enhance, and subsequent development on the next image of a periventricular lesion seen on 
both unenhanced T2-weighted image (middle) and Gd-enhanced T,-weighted image (right). 
In another patient one lesion was seen to reenhance on a second follow-up scan. This means 
that the total number of occasions when lesions were seen to enhance in this study was 60. 
Thus, the mean number of enhancing lesions encountered when enhancement was present was 
2.3. In two cases new enhancing lesions were actually reactivated preexisting lesions, and 
in two cases ring enhancement was noted (Figure 4). Of the new enhancing lesions, 34 were 
smaller than 5 mm, and 16 were larger. Most (94%) of the enhancing lesions were located 
supratentorially, with 27 in the left hemisphere (vs 20 in the right), most of which were 
located in the frontal lobes (n=25) and parietal lobes (n=16). Only eight (16%) of the new 
enhancing lesions were periventricular (Figure 2). 
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Figure 3. Case 3. Upper row: T2-weighted image at level of basal ganglia of patient С shows 
a new lesion in right temporal lobe (left) which is hyperintense and not very sharply 
demarcated and enhances with Gd on T
r
weighted image (right). Middle row: on next month's 
scan, this lesion has become considerably smaller on T2-weighted image (left) and does not 
enhance (right), while a new enhancing lesion has appeared in left external capsule. Bottom 
row: scan obtained 2 months later shows that both lesions are still present on T2-weighted 
image (left), but do not enhance any more (right). 
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Four lesions were not visible on the corresponding T2-weighted images, while three others 
(two of which were in the gray matter) were recognized only with great difficulty 
(retrospectively) and would otherwise probably not have been seen. Of the remaining 43 
lesions that were shown on T2-weighted images, 31 were clearly visible and 12 were poorly 
seen. Most new lesions appeared in the supratentorial deep white matter. A total of 21 lesions 
(46%) "disappeared" on the T2-weighted images in a mean time of 3.5 months (SD, 2.7 
months; range, 1-9 months). In several instances it was noted that lesions had become very 
small, were absent on one scan, then reappeared once more and finally "disappeared" 
completely. Of the lesions that eventually "disappeared", 80% were initially smaller than 5 
mm, while of the lesions that eventually remained visible 48% were initially larger than 5 
mm (chi-square 4.2, p=.04). The mean follow-up time of lesions that remained visible (10 
clearly, 13 poorly and three retrospectively) was 5.3 months (SD, 2.4 months; range, 1-9 
months). One lesion was first seen on the last scan (no follow-up). Interestingly, one lesion 
started out without being seen on T2-weighted images, but became visible (and remained so) 
on the follow-up scans. A generally recognized pattern was that new lesions were not very 
sharply demarcated and hyperintense on the T2-weighted images at first, but became a little 
smaller, better demarcated, and less intense on the first follow-up scans (Figure 3). On the 
follow-up scans, the sizes and signal intensity of the lesions usually decreased, and they 
sometimes totally disappeared. 
Clinical and MR imaging correlation. In Table 1 the timing of the clinical relapses has been 
marked. All five clinical relapses occurred at time of Gd-enhancement. On the other hand, 
on 21 occasions new Gd-enhancement or reenhancement was seen without an accompanying 
clinical relapse. The kappa coefficient for interobserver agreement (Gd-enhancement vs 
clinical relapse) was 0.21 (0 means no agreement, 1 means complete agreement). In one 
patient, seven lesions were seen to enhance on more than one occasion, at about the time of 
her first clinical relapse. The patients that initially had optic neuritis showed substantially 
more new lesions than those who initially had somatosensory symptoms. In two of the three 
patients who had a somatosensory relapse, new lesions were found in the contralateral parietal 
region, but in the third the only new lesion was found in the temporal lobe. In the other two 
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relapses, clinical symptoms were confined to regions outside the brain (bladder or optic 
nerve), but new lesions were found nevertheless. 
Figure 4. Case 5. Unenhanced T2-weighted image (left) shows multiple lesions. One month 
later left frontal lesion has clearly grown on unenhanced T2-weighted image (middle), and 
shows ring enhancement at periphery of lesion on T,-weighted image (right). 
Discussion 
One of the most striking findings in this study, as in previous studies on the same subject 
(Isaac et al., 1988; Koopmans et al., 1989; Willoughby et al., 1989; Thompson et al., 1991 
and 1992; Harris et al., 1991), is the considerable amount of so-called "silent disease 
activity". The kappa coefficient for interobserver agreement (presence of Gd-enhancing lesions 
vs clinical relapses) was poor. In fact, although all of the clinical relapses were accompanied 
by new enhancing lesions, only 19% of the new MR lesions were accompanied by clinical 
disease activity. Enhancement lasted less than 2 months in 86% of the lesions, while only 4% 
was seen to enhance for more than 2 months, which is in accordance with previous findings 
(Thompson et al., 1991 and 1992; Harris et al, 1991). 
The use of gadopentetate dimeglumine led to the detection of seven new lesions (not visible 
or only retrospectively visible compared with 43 lesions that were clearly visible on the T2-
weighted images). In addition one reenhancing lesion and nine lesions with persistent 
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enhancement were observed. In total 40% more disease activity was detected with Gd-
enhancement. An additional advantage of the use of Gd lies in the interpretation of equivocal 
changes on T2-weighted images, especially in case of suboptimal repositioning or in case of 
large numbers of préexistent lesions. Our results support the concept that sequential contrast-
enhanced MR imaging frequently shows clinically silent disease activity in RR MS. 
New lesions were preponderantly seen in the supratentorial deep white matter, despite the 
characteristic finding of periventricular white matter lesions in MS (see for example diagnostic 
MR criteria for MS by Paty et al. (1988). We found a poor correlation between the initial 
lesion score and the subsequent development of new enhancing lesions. The three patients 
that initially had optic neuritis, had a higher frequency of developing new lesions on brain 
MR imaging than the patients who initially had somatosensory symptoms. 
The follow-up scans showed that 46% of the lesions eventually "disappeared" on the T2-
weighted images, especially smaller lesions. The subject of "disappearance" of lesions is a 
controversial one. At this time it is impossible to decide whether lesions completely resolve 
or just "disappear" beyond the scanner resolution. To be able to identify new lesions with 
certainty (Figures 2-4), identical slice repositioning is essential (Figure 1). Quantitative 
assessment of reproducibility would be preferable, but as this is difficult to perform, we chose 
to assess reproducibility in a subjective fashion. More than 75% of the repositioning was 
graded as good. On those MR images, the inaccuracy in any direction was less than half a 
slice in thickness, or 2.5 mm. As the width of the brain is at least 12 cm, this implies an 
angulation error of less than 1.2 degrees (tan"1 [2.5/120]). The fact that some small lesions 
were not seen on the T2-weighted images and later "reappeared" may be related to small 
fluctuations in repositioning accuracy, resulting in artificial "disappearance" of smaller lesions 
in the interstice gap or as a result of volume averaging with normal-appearing brain tissue 
and subsequent loss of contrast. In two patients in whom repositioning was less successful, 
the anatomical landmarks chosen could have been difficult to identify, or, alternatively, it may 
have been difficult for them to lie still during the examination. Perhaps in the future the whole 
brain can be imaged with three-dimensional acquisitions, covering the whole brain within a 
reasonable period of time, allowing the choice of an arbitrary plane of evaluation on 
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postprocessing. 
In MS, an exacerbation (bout, episode, attack) is defined as the occurrence of a symptom or 
sign of neurologic dysfunction, with or without clinical confirmation, lasting longer than 24 
hour (Poser et al., 1983). The number of exacerbations, defined in this way, is widely used 
as a parameter in treatment trials. In our patients, the number of new enhancing or 
reenhancing lesions detected with MR imaging was 4.2 times the number of clinical relapses. 
Subjective clinical scoring systems, such as the widely used EDSS, have a high interrater 
variability (Noseworthy et al., 1990; Francis et al., 1991). This means that a large change 
(1.0 point) in score (on a scale of 0-10) is necessary to show a clinically significant change 
in disease course (Noseworthy et al., 1990). This could imply that moderately effective 
treatments are not appreciated as such, because the outcome measure (i.e. EDSS score) is 
not sensitive enough. During the study period a change in the EDSS score of at least 1.0 
points occurred in only three out of five relapses and all exit scores were identical to the entry 
scores, while a substantial amount of disease activity was detected with MR imaging. 
Several sequential MR studies have been performed in MS with different disease courses. It 
has been shown that patients with RR and SP MS (together 85% of the patients) frequently 
have new lesions. Table 2 gives an overview of these studies and the present study. 
One of the most striking points is the enormous variation in the number of new lesions per 
month. For example in four studies, patients with RR MS were examined with a relatively 
short disease duration, and revealed a mean number of new lesions per month varying from 
0.2 to 3.35 (factor 17). Several technical and clinical parameters of those studies have also 
been listed and show substantial inhomogeneity. We performed a weighted (by the number 
of patients per study) multiple regression analysis with the mean number of new lesions as 
dependent variable and field strength, disease duration, sex ratio, relapse rate, use of Gd and 
progression rate (defined as EDSS score/disease duration) as independent variables. 
The fitted model explained most (89%) of the variance in the mean number of new lesions. 
The variance explained by field strength was 28 %, by disease duration 28 %, by sex ratio 2 %, 
by relapse rate 8%, by use of Gd 12%, and by progression rate 26% (percentages do not bj 
definition have to add up to 89% or 100%). This regression analysis thus shows that a 
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substantial paît of the variance in the mean number of new lesions per patient between those 
studies can be explained by variations in the parameters listed in Table 2. Causal relationships, 
however, are not demonstrated by this analysis, as for example, field strength is strongly 
correlated with geographical distribution of the imaging centers involved. It does demonstrate, 
however, that several clinical factors, among them disease duration and progression rate, can 
explain a fair amount of the variance between different studies. The analysis suggests that 
homogeneity in study design should extend from technical to clinical design. In addition to 
the selection of a homogeneous study group according to disease course (Thompson et al., 
1991 and 1992), matching of other clinical factors between treatment and placebo groups in 
order to increase precision might be needed as well. 
Table 2. Serial MR imaging studies of the brain in patients with MS. 
reference no. [1] [2] [3] [4] [5] [6] This study 
disease course 
no. of patients 
mean age (years) 
EDSS at entry 
dis. dur. (mo's) 
sex ratio (F/M) 
relapse rate/mo 
progression rate 
Magnet (T) 
Gd used 
new lesions/ mo 
RR 
7 
27 
3.0 
5.7 
1.5 
0.12 
0.53 
0.15 
no 
0.50 
RR 
9 
30 
0.5 
5.0 
1.3 
0.04 
0.10 
0.15 
no 
0.20 
®SP 
8 
45 
6.1 
15.0 
1.0 
0 
0.41 
0.15 
no 
1.00 
SP 
12 
35 
5.2 
7.8 
'0.5 
0.28 
0.67 
0.5 
yes 
1.50 
RR 
6 
34 
1.9 
1.4 
5.0 
0.03 
1.36 
1.5 
yes 
3.35 
RR 
5 
30 
3.0 
4.0 
'4.0 
0.27 
0.75 
0.5 
yes 
1.46 
RR 
7 
24 
1.6 
2.7 
1.3 
0.10 
0.59 
0.6 
yes 
0.86 
[l]:Isaac et al. (1988), [2]:Willoughby et al. (1989), [3]:Koopmans et al. (1989), [4]: Thompson et 
al. (1991), [5] rHarris etal. (1991), [6]:Thompsonera/. (1992). Progression rate = EDSS score/disease 
duration. "Personal communication (information about the number of men/women was not provided 
in the original papers, but was later obtained in personal communication). °One patient had a primary 
progressive disease course. 
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In conclusion, our results support the concept that contrast-enhanced MR imaging is more 
sensitive than clinical monitoring in detecting new disease activity in RR multiple sclerosis. 
If we assume that the development of new MR abnormalities will ultimately be accompanied 
by clinical deterioration, then sequential contrast-enhanced MR imaging might be used as an 
outcome parameter in pilot studies of putative therapeutic regimens, as it could reduce the 
number of patients and the follow-up time needed to demonstrate a treatment effect. 
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A CORRELATIVE TRIAD OF GADOLD4IUM-DTPA MRI, EDSS, AND CSF-MBP 
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Methylprednisolone and MRI/CSF MBP in MS 
Introduction 
BBB disruption is an early (Grossman et al, 1988; Miller et al, 1988; Bastianello et al, 
1990) or even preceding (Kermode et al, 1990) feature in the acute stage of lesion 
development in MS. BBB disruption can be demonstrated by means of Gd-DTPA using 
MR imaging. A recent study showed that high-dose IV MP improved BBB integrity in 
MS, as judged from changes in Gd-DTPA enhancement (Barkhof et al, 1991). Improved 
BBB integrity was found to correlate with clinical improvement. 
CSF examination yields typical abnormalities in MS patients, which reflect the 
immunological status of the patient. After MP treatment, changes in CSF variables occur, 
which consist of reduction of MBP (Frequin et al., 1991; Warren et al., 1986), anti-MBP 
(Warren et al, 1986; Wajgt et al, 1983), and reduction of intrathecal IgG-synthesis 
(Frequin et al, 1991; Warren et al, 1986; Durelli et al, 1986; Compston et al, 1987); 
a reduction of the number OB with iso-electric focusing has been found by Frequin et al 
(1991), but not by Durelli et al (1986). There is no clear correlation between CSF and 
clinical findings, except for CSF-MBP which is raised at times of relapse (Cohen et al, 
1980; Martin-Mondière et al, 1987), and is undetectable in the remission phase (Warren 
étal, 1987). 
We hypothesize that there is a correlation between Gd-DTPA enhancement and some CSF 
variables, as they all express activity on an immunological level. The purpose of the 
present study to investigate a) whether there is a relation between clinical findings, Gd-
DTPA enhanced MR imaging and CSF variables in relapsing MS patients before 
treatment and b) whether MP-induced changes in clinical findings and Gd-DTPA 
enhanced MR imaging relate to changes in CSF variables. 
Patients and methods 
Patients. Sixteen patients (12 women, 4 men) with definite MS (Poser et al, 1983), were 
prospectively investigated. The mean age of the patients was 34 years (range, 22 to 45), 
the mean DD 6.8 years (range, 1 to 15). All patient were treated because of a 
symptomatic deterioration lasting longer than 24 hours, without subsequent spontaneous 
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improvement. Treatment consisted of MP administered IV during 15 minutes in a dose of 
1 gram daily for 10 consecutive days. Four patients were treated twice (at least 3 month 
apart). A total of 20 consecutive courses was thus given and used for analysis. Spinal taps 
and MR scans were performed before and after MP treatment. The mean interval between 
the first tap and first MR scan was 8.6 days (range, 0 to 22); the mean interval between 
the second tap and second MR scan was 4.2 days (range, 0 to 14). EDSS-scores 
(Kurtzke, 1983) were assessed before and after therapy simultaneously with the CSF 
examination, by an examiner (O. R. H.) who was blinded to the MR and CSF findings. 
MR imaging was performed on a 0.6 Tesla system (Technicare, Solon, Ohio, USA) 
before and after treatment using a standard head coil. Repositioning errors were corrected 
by means of 3 consecutive oblique scout images (transverse, coronal, sagittal). Gd-DTPA 
dimeglumine (Magnevist™, Schering AG) was administered intravenously in a dose of 
0.2 mmol/kg, followed by a post-injection flush with 10 cc saline. Axial (double oblique) 
series were made according to internal landmarks (caudal borders of the pituitary gland 
and the fastigium of the 4th ventricle for angulation; caudal border of the splenium of the 
corpus callosum as Z-centre). T
r
weighted SE sequences were obtained (repetition time 
400 ms/ echo time 28 ms/4 excitations) starting 5-10 minutes after Gd-DTPA injection, 
with an in-plane resolution of 1.0 χ 1.3 mm, and a slice thickness of 5 mm (gap 1.25 
mm). MR scans were analyzed by 2 of the authors (F. В., P. S.) in conference; they 
were unaware of the clinical and CSF findings. An area of markedly increased SI, not 
related to a physiologically enhancing structure, and consisting of at least 3 pixels, was 
considered a Gd-DTPA enhancing lesion. The number, not the size, of Gd-DTPA 
enhancing lesions was used as study-parameter. 
CSF examination was performed before and after treatment. CSF analysis included 
mononuclear cell count, albumin-quotient (Q-albumin), intrathecal IgG-synthesis, number 
of OB's on iso-electric focusing and CSF-MBP. IgG and albumin were measured in 
unconcentrated CSF and diluted serum (1:400). Sheep antihuman IgG (Boehringer, 
Mannheim) and rabbit antihuman albumin (Behringwerke, Marburg) were used. Q 
albumin was defined as albumin-CSF/albumin-serum. The calculation of intrathecal IgG 
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synthesis (intrathecally produced IgG) was performed according to the hyperbolic Reiber 
formula (Reiber and Felgenhauer, 1987). Iso-electric focusing was performed with 
Ampholine PAG-plates (by LKB; Ph 3.5-9.5). MBP was determined according to the 
instructions of the manufacturer (Diagnostic Systems Laboratories, Webster, Texas) using 
a double antibody RIA-kit containing human basic protein (whole molecule) as antigen 
and rabbit anti-human MBP as anti-serum. Goat anti-rabbit gamma-globulin was used as 
MBP precipitation reagent. Human MBP (J 125 2 /xCi/vial) was included in the test-kit. 
Statistical analysis was performed using the SPSS/PC™ statistical package. Data before 
and after treatment were compared by means of a Wilcoxon matched-pairs signed-rank 
test. Relations between clinical, MR and CSF data were investigated by means of 
Pearson's correlation coefficients. Nulhypotheses were tested two-sided and ρ values 
smaller than 0.05 were considered statistically significant; ρ values between .05 and .1 
were considered as trends. 
Results 
Before MP-treatment, the median EDSS-score was 3.5 (mean 4.2), 84 Gd-DTPA 
enhancing lesions were seen in 16 of 20 scans (4 scans showed no enhancement) and all 
mean values of the investigated CSF variables, except Q-albumin, were abnormal. 
Following treatment a reduction in EDSS score (median, 1.0) was observed (after 15 of 
20 courses improvement was seen). Table 1 shows the mean values of clinical, CSF, and 
MR findings before and after treatment. Insignificant reduction in mononuclear cells 
(25%), OB's (6%), and Q-albumin (18%) were found after MP-treatment. Following 
treatment there was a significant reduction of the number of Gd-DTPA enhancing lesions 
(76%; 3 of 16 scans showed less enhancement and 9 of 16 scans showed no 
enhancement), intrathecal IgG synthesis (66%), and CSF-MBP level (74%). After 
treatment, only the mean CSF-MBP level returned to reference values, while the mean 
values of all the other CSF variables investigated remained elevated. Table 2 displays the 
initial EDSS-scores, and changes after MP-treatment in EDSS, Gd-DTPA enhancement 
and CSF-MBP for the individual patients. 
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The relation between Gd-DTPA enhancement, EDSS-score and CSF variables before 
treatment is shown in table 3. Only the number of Gd-DTPA enhancing lesions and the 
CSF-MBP level correlated significantly. Trends were noted in the relation of Q-albumin 
to Gd-DTPA and in the relation of CSF-MBP to EDSS. There were no correlations of 
age or DD with either the EDSS-score or the number of Gd-DTPA enhancing lesions 
before treatment (not shown in table). 
Table 1. Results of median EDSS and mean MR and CSF variables before and after high-dose intravenous 
MP treatment. 
variable refererence before (range) SD after (range) SD ρ value 
EDSS score 
Gd-lesions 
mono's 
IgG synthesis 
number of OB 
CSF-MBP level 
Q Albumin 
0 
0 
<9/3 mm1 
0 mg/1 
0 
<. 1.5 mug/1 
< 670 
3.5 (2-7) 
4.1 (0-33) 
17.4 (0-78) 
23.6 (0-135) 
3.4 (0-12) 
12.3(0-11.6) 
612 (264-1,217) 
1.3 
7.9 
16.3 
32.8 
3.2 
3.3 
217 
2.25 (2-6) 
1.0 (0-14) 
13.0 (2-49) 
8.1 (0-34) 
3.2 (0-13) 
0.6 (0.2-2.5) 
578 (296-1,191) 
1.2 
3.1 
11.9 
9.0 
3.3 
0.5 
227 
0.0007 
0.0037 
NS 
0.0053 
NS 
0.0042 
NS 
Legend: P-values were calculated using Wilcoxon's matched pairs signed rank test. SD: standard deviation; 
NS: not significant; mono's: number of mononuclear cells; IgG synthesis: intrathecal IgG synthesis; OB: 
oligoclonal band; MBP: myelin basic protein; Q Albumin: albumin quotient (xlO5). 
The relation between the change in EDSS score and number of Gd-DTPA enhancing 
lesions on one hand and change in CSF variables on the other hand is shown in table 3. 
Significant relations were found in the decrease in the number of Gd-DTPA enhancing 
lesions to the decrease in EDSS-score and in the relation of decrease in CSF-MBP level 
to both decrease in EDSS-score and decrease in the number of Gd-DTPA enhancing 
lesions. A trend was noted towards a negative correlation of the decrease in the number 
in Gd-DTPA enhancing lesions and the change in the number of OB's. There was a 
significant relation of the difference in EDSS score with the initial EDSS score (r=0.631, 
p=0.003) and with age (r=-0.464, p=0.039), and a trend in the difference of the number 
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Gd-DTPA enhancing lesions with either initial EDSS-score (r= 0.398, p=0.08) or age 
(r=-0.390, p=0.09). The DD did not correlate with the difference in both EDSS-score or 
the number of Gd-DTPA enhancing lesions (not shown in table). 
Table 2. Clinical data and treatment effect on EDSS, Gd-DTPA, and CSF-MBP for the individual patients, 
patient age sex DD entry-EDSS Ô-EDSS ÛGdDTPA û-CSF-MBP 
A 
В 
С 
D 
El 
E2 
Fl 
F2 
Gl 
G2 
Hl 
H2 
I 
J 
К 
L 
M 
Ν 
О 
Ρ 
35 
34 
39 
30 
26 
39 
33 
27 
22 
28 
35 
36 
27 
45 
39 
29 
M 
F 
F 
F 
M 
F 
F 
F 
F 
F 
F 
M 
F 
F 
F 
M 
15 
1.5 
15 
4 
1.5 
2.5 
2.5 
3 
1.5 
3.5 
5 
6 
4.5 
24 
10 
10 
3.0 
3.0 
4.0 
6.0 
5.0 
7.0 
3.0 
3.0 
4.0 
3.0 
2.0 
3.0 
3.0 
6.0 
3.0 
4.0 
5.0 
7.0 
3.0 
6.0 
1.0 
1.0 
2.0 
0 
2.0 
5.0 
0 
1.0 
1.5 
1.0 
0 
1.0 
1.0 
2.0 
0 
1.0 
2.0 
1.0 
0 
3.0 
0 
0 
0 
4 
19 
17 
0 
0 
0 
1 
1 
1 
1 
5 
10 
-1 
0 
1 
1 
3 
0.70 
-0.30 
5.30 
0.30 
4.10 
5.50 
0 
-0.30 
0 
0.80 
-O.10 
0.10 
0.10 
1.30 
7.40 
0.30 
0.20 
0.30 
0 
9.10 
Legend: Û-EDSS, Û-Gd, Ô-CSF-MBP: change in EDSS score, number of Gd-lesions and CSF MBP 
level following treatment. DD: disease duration. 
Discussion 
MR imaging is a very sensitive tool in the assessment of MS lesions (Paty et al., 1988; 
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Uhlenbrock et al, 1988; Baumhefner et al, 1990). Lesions on T2-weighted images can 
not differentiate the separate pathological stages of lesion development and represent both 
active and inactive disease. The lesion load on T2-weighted MR imaging represents 
predominantly disease activity in the past and is subject to small fluctuations only; some 
have found these to correlate with the EDSS-score (Truyen et al., 1990), and with neuro-
psychological testing (Baumhefner et al., 1990; Roa et al., 1989). The number of hyper-
intens foci on T2-weighted images has previously been found to correlate with intrathecal 
IgG-synthesis (Baumhefner et al., 1990; Baum et al., 1990), but not with the number of 
mononuclear cells (Baum et al, 1990) or OB's (Baumhefner et al., 1990). The relation of 
CSF-MBP to the number of hyperintens foci has never been investigated. MR imaging is 
capable of separating lesions with and without BBB disruption by means of Gd-DTPA 
(Grossman et al, 1988; Miller et al, 1988; Bastianello et al, 1990; Kermode et al, 
1990; Barkhof et al, 1991). The relation of Gd-DTPA enhancement to CSF findings has, 
to our knowledge, never been investigated. 
Table 3. Relation between EDSS scores, Gd-DTPA enhancement and CSF variables, expressed as 
Pearson's correlation coefficients. 
Gd-lesions 
mono's 
intratecal IgG 
OB 
CSF-MBP 
Q albumin 
number of Gd-lesions 
before 
treatment 
0.12 
-0.05 
-.27 
0.46 (pi=0.040) 
0.40 (p=0.079) 
treatment 
effect 
0.13 
-0.16 
-0.44 (p= 
0.56 (p= 
0.37 
=0.053) 
0.011) 
EDSS-score 
before 
treatment 
0.13 
-0.06 
0.23 
0.12 
0.39 (p=0.086) 
0.32 
treatment 
effect 
0.50 (p=0.026) 
0.00 
0.02 
-0.36 
0.52 (p=0.020) 
0.36 
Legend: See Table 1. The Pearson's correlation coefficients shown are not statistically significant, unless 
otherwise specified (p values). 
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Gd-DTPA enhanced MR imaging and some CSF variables present information about the 
separate (early) stages of lesion development or disease activity at present and are subject 
to major fluctuations (Grossman et al., 1988; Miller et al., 1988; Bastianello et al., 1990; 
Warren et al., 1987; Thompson et al., 1987; Thompson et al., 1983). We hypothesized 
that there would be a relation between Gd-DTPA enhancement and (some) CSF variables. 
Before treatment a significant relation was found between the number of Gd-DTPA 
enhancing lesions and the level of CSF-MBP. If Gd-DTPA enhancement stands for active 
inflammation (Katz et al., 1990; Hawkins et ai, 1990; Kuharik et al, 1988), and CSF-
MBP stands for demyelination (Warren et ai, 1987), the volume of inflamed tissue 
relates to the amount of myelin being damaged and indicates that inflammation is directly 
accompanied (and not followed) by demyelination. Evidence for the occurrence of 
demyelination early in the development of lesions is also found in the demonstration of 
lipid peaks in the MR spectra of new lesions (Wolinsky et al., 1990). 
The intrathecal IgG synthesis is usually elevated during the remission phase of MS 
(Thompson et al., 1987; Caroscio et al., 1986), and therefore seems not especially linked 
to current disease activity. This might explain the correlation reported between intrathecal 
IgG-synthesis and T2-weighted MR imaging (Baumhefner et al., 1990; Baum et al., 
1990), and the absence in our study of a correlation between intrathecal IgG-synthesis and 
Gd-DTPA enhancement. The number of OB's, although not constant over time 
(Thompson et al., 1983), is not subject to great variations Thompson et al., 1983; 
Thompson et al., 1987), and the absence of a correlation with Gd-DTPA enhancement is 
therefore not surprising. 
The rationale for immunosuppressive treatment, such as MP-treatment, is to suppress the 
inflammatory reaction of the immune system, in order to prevent or stop the process of 
demyelination (Warren et al., 1987; Thompson et al., 1989). In the present study a 
significant decrease of intrathecal IgG-synthesis (Frequin et al., 1991; Warren et al., 
1986; Durelli et al., 1986; Compston et al., 1987), and CSF-MBP levels was found 
(Frequin et al., 1991; Warren et al., 1986) after MP-treatment, but not of OB's (Wajgt et 
al., 1983), mononuclear cells count or Q-albumin. The CSF-MBP level, however, was 
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the only CSF variable to return to reference values. Interestingly, the decrease in CSF-
MBP level correlated significantly with the decrease in the number of Gd-DTPA 
enhancing lesions and EDSS-score. After high-dose IV MP treatment both Gd-DTPA 
enhancement and CSF-MBP levels improved in a similar way, which might indicate that 
its clinical action is accompanied by improved BBB integrity and decreased myelin 
breakdown. The changes in other CSF variables did not correlate with the decrease in 
Gd-DTPA enhancement. A remarkable trend towards a negative correlation of change in 
Gd-enhancement and change in number of OB's was found. Perhaps the development of 
OB's takes some time, but is indeed dependant on the disruption of the BBB, to allow 
migration of lymphocytes to reach the CSF space. 
There was a trend towards correlation of the number of Gd-DTPA enhancing lesions and 
the Q-albumin before treatment, but the decrease in the number of Gd-DTPA enhancing 
lesions following MP-treatment showed no significant relation with the changes in 
albumin-quotient (not significantly lower), although both represent BBB-integrity. In 
animal studies of experimental allergic encephalitis enhancement of Gd-albumin complex 
was only seen in 4 out of 6 Gd-DTPA enhancing lesions, while in 2 of these lesions the 
extent and intensity was less than with Gd-DTPA (Hawkins et al., 1990). The molecular 
weight of Gd-DTPA (550 Da) and albumin (60kDa) is considerably different, as might 
their routes of transport across the BBB be, thereby giving a possible explanation for the 
absence of a good correlation. 
The correlative triad of clinical improvement, restoration of BBB-integrity and decrease 
of myelin breakdown following MP-treatment is certainly one of the most salient finding 
of this study. The decrease in recent lesions after MP is accompanied by a decrease in 
myelin breakdown. The changes in EDSS, Gd-DTPA, and CSF-MBP could have been the 
result of the natural course. We think, however, that the finding of a correlative triad 
pleads against this. Placebo-controlled studies could clarify this issue. If the changes in 
and CSF-MBP are indeed the result of MP treatment it is impossible to decide from these 
data whether they are primary result, i.e. that MP actually interferes with the process 
responsible for demyelination, or that they are a secondary result, i.e., that MP only 
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interferes nonspecifically with the mediators of the disease process or acts directly on the 
BBB and in that way prevents the transfer of mononuclear cells into the brain (Long and 
Holaday, 1985). The fact that the number of mononuclear cells and OB's did not drop 
significantly might indicate that the inflammatory process is not completely stopped after 
MP treatment (or that both variables are not correlated with acute inflammatory activity in 
the brain). 
Both age and initial EDSS score showed a significant correlation with the change in EDSS 
after treatment, but not with the decrease in Gd-DTPA enhancement, which might 
indicate that there was some favourable change after treatment (decreased BBB 
disruption), which was not appreciated by the EDSS scoring system in relatively older or 
less disabled patients. Clinical disease activity as assessed by the EDSS mainly represents 
the result of lesions in the brainstem and spinal cord. Serial MR studies have shown that 
MR activity is far more frequent (especially in so-called "silent regions") than clinical 
activity. It therefore is far from surprising that there is no perfect correlation of Gd-
DTPA enhancement and EDSS changes. 
The finding of a correlative triad of (changes in) CSF-MBP, Gd-DTPA enhancement and 
EDSS (following MP-treatment), indicates that these variables might become of more 
importance for the evaluation of progression of the disease and for monitoring clinical 
trials in addition to ordinal clinical scoring systems like the EDSS with their fallacious 
pitfalls (Noseworthy et al, 1990; Francis et al., 1991). When substantiated this could 
have implications for the population size and follow-up time needed to able to 
demonstrate a certain effect of putative drugs in treatment trials in MS. 
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Methylprednisolone and MRl/CSF analysis in MS 
High-dose intravenous methylprednisolone (MP) 
Multiple sclerosis (MS) is an inflammatory and demyelinating disease of the central 
nervous system of unknown origin. High-dose intravenous methylprednisolone (MP) often 
has a beneficial effect in the treatment of acute relapsing MS. In relapsing MS patients, a 
significant decrease in clinical disability scores is reported after MP, compared to 
controls, placebo or other therapy regiments (Barnes et al., 198S; Durelli et al., 1986; 
Milligan et al., 1987). It is unknown what the mode of action of MP is in MS patients; 
how the immune response is influenced and the myelin breakdown is tempered or altered 
is not well understood. Different studies (Frey, 1989) demonstrated the following effects 
of MP: 1. Improvement of the blood brain barrier (BBB) leakage or disruption in acute 
demyelinating lesions (Troiano et al., 1984; Barkhof et al., 1991; Bumham et al, 1991; 
Miller et al., 1992). 2. Decrease of oedema in the acute lesions. 3. Reduction and 
modulation of inflammatory mediators (cytokines, proteases) by interference with 
monocyte-macrophage function. 4. Change in lymphocyte function and decrease in 
number of T-lymphocytes with a reduction of T-helper (CD4+) cells to a greater extent 
than the T-suppressor (CD8+) cells, resulting in a decrease of the ratio of T-helper/T-
suppressor. 5. Inhibition of the early activation of B-cells with decrease of the production 
of immunoglobulines. 6. Reduction of myelin basic protein (MBP), anti-MBP, and myelin 
associated glycoprotein (MAG). New insight into the mode of action of corticosteroids 
have been obtained from studies using (gadolinium-enhanced) magnetic resonance (MR) 
imaging and cerebrospinal fluid (CSF) parameters as measures of disease activity. 
MR imaging 
For the detection and follow-up of MS lesions MR imaging of the brain is the most 
appropriate and sensitive method (Paty et al., 1988; Koopmans et al., 1989). Most of the 
MS lesions, visualized by MR, are asymptomatic. Serial MR imaging studies in MS 
patients have shown five to ten times more new lesions than clinical relapses (Kappos et 
al., 1988; Willoughby et al., 1989; Thompson et al., 1991) and indicate that MS patients 
have a dynamic continuous spectrum of disease activity of MS lesions, even in clinically 
HI 
stable MS (Harris et al, 1991, Truyen et al., 1991). Before the application of MR 
imaging to the brain this silent disease activity went undetected in clinically stable MS 
patients. 
Gadolinium-enhanced MR imaging 
Recently different studies (Gonzalez-Scarano et al., 1987; Miller et al., 1988; Kermode et 
al., 1990a; Bastianello et al., 1990) have indicated that gadolinium enhancement on MR 
probably represents one of the first stages of lesion development in MS, because acute 
inflammatory demyelinating lesions are accompanied by disruption of the BBB. The 
phenomenon of gadolinium enhancement probably stands for BBB leakage and 
inflammation in MS (Katz et al., 1990) and is also found in animal studies with chronic 
relapsing experimental autoimmune encephalomyelitis (EAE) (Hawkins et al., 1990; 
Kuharik et al., 1990). Nearly all new lesions show enhancement assessed by serial MR 
imaging in relapsing remitting and secondary progressive MS (Miller et al., 1988; 
Kermode et al, 1990b; Harris et al, 1991; Thompson et al, 1991). Gadolinium 
enhancement on MR is transient and generally persists for less than 2-6 weeks in most of 
the lesions (Bastianello et al, 1990; Harris et al., 1991). It is an objective variable which 
can be used as an outcome measure in therapeutic clinical trials and for monitoring 
disease activity (Miller et al, 1991; Barkhof et al, 1991; Harris et al, 1991; Bumham 
et al, 1991). 
Because gadolinium enhancement represents the acute stage of development of the MS 
lesion, some relationship between clinical disability and enhancement might be expected, 
(e.g. that patients with frequent enhancing lesions will have a higher risk for developing 
disability). A perfect correlation, however, does not exist because there are "silent 
regions" in the CNS and most of the clinical disability as assessed by disability scores 
(Kurtzke, 1983) is derived from lesions in the brainstem and spinal cord. Therefore the 
size and site of the enhancing lesions are important for clinical expression. In one study 
(Harris et al, 1991), no correlation was found with the number or place of enhancing 
lesions but the spinal cord was not imaged. In an other study (Truyen et al, 1991), using 
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a standardized non-contrast-enhanced MR imaging protocol for long-term follow-up 
including the imaging of the cervical cord, significantly more and larger changes in 
relapsing MS patients were reported than in clinically stable patients. These authors 
concluded that MR imaging may be a good indicator for global disease activity. 
CSF measurements 
In contrast to the results of the gadolinium-enhanced MR imaging, there are only a few 
CSF parameters which have a clear consistent correlation with disease activity of MS 
patients. Intrathecal IgG synthesis and oligoclonal banding pattern seem not closely linked 
to current disease activity, although conflicting results have been reported (Thompson et 
al, 1987; Caroscio et al, 1986; Farrell et al, 1985). The most useful parameters in 
clinical practice are perhaps myelin basic protein (MBP) in the CSF and intrathecal 
immunoglobulin M synthesis. 
Elevated levels of CSF MBP have been detected in MS patients with active disease 
indicating myelin breakdown (Cohen et al, 1976; Cohen et al, 1980; Whitaker, 1984). 
In another study (Martin-Mondiere et al., 1987), CSF MBP was not detected in any MS 
patient with inactive or slowly progressive disease nor in any patient during exacerbations 
with only recurrence of old signs or symptoms. 
Recently, several studies about intrathecal IgM in MS are published. In one study (Sharief 
and Thompson, 1991), intrathecal production of IgM assessed by IgM oligoclonal bands 
in CSF was found to correlate with disease activity manifesting as a recent relapse as well 
as with the total number of relapses. CSF oligoclonal IgM seems to be a good indicator 
of recent immunological stimulation in MS (Sharief and Thompson, 1989). Both 
parameters, CSF MBP and intrathecal IgM, might be useful in evaluating therapy in MS, 
and to assess disease activity. 
Effect of high-dose intravenous MP on gadolinium-enhanced MR imaging 
High-dose intravenous MP seems to have no significant short-term effect on white matter 
lesions visualized on long TR (T2 -weighted) unenhanced scans (Kesselring et al., 1989; 
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Rumbach et ai, 1990). A few MRI studies have assessed the effects of high-dose 
intravenous MP on gadolinium enhancement. We studied 12 MS patients who received 
1000 mg intravenous MP daily for 10 consecutive days (Barkhof et al., 1991). We found 
a marked decrease of gadolinium enhancement after MP, which correlated well with the 
clinical improvement (Figures 1 and 2). The correlation coefficient between the change in 
EDSS and change in gadolinium enhancement was 0.55. In another study, after high-dose 
MP, suppression of gadolinium enhancement was also found which temporarily correlated 
with changes of the clinical disability (Bumham et al., 1991). In a recent study (Miller et 
al., 1992), the same results were found with suppression of gadolinium enhancement. 
New enhanced lesions developed after 1 month of follow-up, indicating a temporarily 
effect of MP. 
Number of lesions 
Total of lesions 
^ H Gad-OTPA enhancing 
F^ -"l T2 representation 
Pre Post 
Pre Post MP treatment 
Figure 2. The effect of MP treatment on MR imaging findings (gadolinium-DTPA 
enhancement and T2 representation) in 12 MS patients. Seven patients received more than 
one MP treatment. Mean EDSS pre treatment was 3.6 and 2.6 after treatment. (Barkhoj 
et al., 1991). 
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Effect of high-dose intravenous MP on CSF measurements 
In a group of 101 patients with definite MS, we determined the levels of CSF 
mononuclear cells, intrathecal IgG and IgM synthesis calculated according the hyperbolic 
Reiber formula (Reiber and Felgenhauer, 1987), oligoclonal banding on iso-electric 
focusing (IEF), and CSF MBP before and after treatment with high-dose intravenous MP. 
All patients had a symptomatic deterioration and were classified as chronic progressive 
(CP; N=47), relapsing remitting (RR; N=37) and the combined group (CP+RR; 
N=17). The mean levels of the different CSF measurements before and after MP 
treatment are shown in Figure 3A-E. 
Before MP treatment, mean CSF MBP levels were significantly (p<0.05) higher in the 
patients with RR (2.1 /tg/1) and CP+RR (2.3 /xg/1) disease course compared to the CP 
(1.3 μg/l) group. A trend (p=0.06) was noted towards a higher intrathecal IgM synthesis 
in the RR (2.8 mg/1) group versus the other 2 groups (CP 0.3 mg/1; CP+RR 1.1 mg/1). 
In the RR group, a weak positive correlation (r=0.34; p=0.06) was calculated between 
CSF MBP and EDSS. After MP treatment, a significant correlation (r=0.39; ρ<0.05) 
was found between the decrease in myelin breakdown (CSF MBP) and clinical 
improvement. 
Conclusion 
The effects of MP on gadolinium-enhanced MRI and CSF measurements indicate 
restoration of the BBB integrity, reduction of CSF mononuclear cells and intrathecal 
immunoglobulin production and decrease of myelin breakdown which parallel clinical 
improvement. 
In a recent study, we have reported a marked correlative triad between gadolinium-
enhanced MS lesions on MRI, EDSS and CSF MBP following MP treatment, indicating a 
clear relationship between restoration of the BBB integrity, clinical improvement, and 
decrease in myelin breakdown (Barkhof et al., 1992). This implies that the effect of MP 
on acute MS lesions is accompanied by a decrease in myelin breakdown. It is not clear 
whether MP primarily interferes with the process of demyelination or that MP reacts non-
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Figure 3. Mean levels of different CSF measurements in 101 MS patients pre and post 
MP treatment given for the disease course. (A) CSF mononuclear cells; (B) Intrathecal 
IgG synthesis; (C) Intrathecal IgM synthesis; (D) Number of oligoclonal bands on iso-
electric-focusing (IEF); and (E) CSF MBP.( * = p<0.01; ** = ρ<0.001; *** = 
ρ< 0.0001; without annotation means not significant). 
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specifically with the mediators of the disease process. It is possible that improvement of 
the BBB damage results in decreased trafficking of inflammatory cells into the CNS and 
prevents myelin breakdown or that MP (indirectly) contributes to the process of 
remyelination. 
In a few MS patients, we had the personal experience that directly after the start of high-
dose intravenous MP treatment a rapid clinical improvement (within 2-3 hours) occurred 
with decrease of signs and symptoms. This could lead to the speculation that there had 
occurred in these patients only BBB pathology and early inflammation which was not 
accompanied by demyelination. A possible expression of this phenomenon might be a 
conduction block accompanied by edema without structural abnormalities. Possibly these 
are "reversible" lesions, with only gadolinium enhancement before and without fixed T2 
representation after MP. Most gadolinium-enhanced lesions on MR imaging, however, are 
represented on T2-weighted images (Barkhof et al, 1991; Harris et al., 1991). 
In conclusion, BBB disruption seems to be a good marker for disease activity in MS. It 
has become clear that clinical improvement after MP is related to improvement of BBB 
integrity. Although BBB restoration is transient and structural abnoralities persist on T2-
weighted images after MP, it is of particular interest that demyelination is apparently 
slowed down simultaneously. 
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Methylprednisolone /long-term effects in MS 
Introduction 
The treatment with high-dose intravenous methylprednisolone (Г МР) is nowadays 
commonly used in neurologic practice to manage acute and progressive exacerbations in 
multiple sclerosis (MS) patients. Several studies have demonstrated a beneficial clinical 
effect of IVMP compared with placebo, untreated patients or patients treated with ACTH 
(Compston, 1988; Troiano et al, 1987; Durelli et al., 1986; Milligan et al, 1987; 
Barnes et al, 1985; Trotter et al, 1980). On a paraclinical level, treatment with IVMP 
in MS causes reduction of intrathecal IgG synthesis, decrease of cerebrospinal fluid (CSF) 
myelin basic protein (MBP), anti-MBP and anti-myelin associated glycoprotein (MAG) 
antibodies (Tourtellotte et al, 1982; Tourtellotte et al, 1980; Compston et al, 1987; 
Baumhefner et al, 1989; Warren et al, 1987; Warren et al., 1986; Wajgt et al, 1983; 
Frequin et al, 1992). Recently, several studies (Barkhof et al, 1991; Barkhof et al, 
1992; Bumham et al, 1991; Miller et al, 1992) have reported on reduction of 
gadolinium-enhancement on magnetic resonance (MR) of the brain in MS patients after 
IVMP, representing restoration of the blood brain barrier (BBB) disruption and decrease 
of inflammation in the acute demyelinating MS lesion. 
Whether the natural course of MS is influenced by IVMP, is unknown. Long-term effects 
have not been studied and need to be assessed. In a longitudinal prospective study with a 
mean follow-up period of 2.6 years, we have followed 46 MS patients treated with 
IVMP. The aim of the present study was to assess the long-term effects of IVMP in 
relapsing and progressive MS, especially the clinical effects and effects on various 
paraclinical variables (immunoglobulines, oligoclonal bands, MBP) in the peripheral 
blood (PB) and CSF of the MS patients. 
Patients and Methods 
Patients. Forty-six patients with definite MS, according to the Poser criteria (Poser et al, 
1983), were prospectively investigated. The disease course (RR= relapsing-remitting, 
CP= chronic progressive, CP+RR= combination), sex, age at entry, disease duration 
(DD), clinical rating according to Kurtzke's Expanded Disability Status Scale (Kurtzke, 
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1983), progression rate, defined as the ratio of EDSS to DD, are summarized in Table 1. 
All patients were treated because of a symptomatic deterioration. Treatment consisted of 
MP administered intravenously during approximately 15-20 minutes in a dose of 1000 
milligram daily for 10 consecutive days. No tapering dose with corticosteroid was used 
after the initial treatment. Every patient was seen three-monthly for clinical analysis; 
when the clinical picture was instable, the patient was seen more often. When necessary, 
IVMP treatment was repeated; when this therapy was not successful intensive immuno-
suppression (IIS) with cyclophosphamide and prednisone (respectively 400 and 100 mgr. 
per day) was given for 20 days under white blood count control. EDSS ratings were 
assessed before and after therapy and during and at the end of the follow-up period 
simultaneously with the peripheral blood (PB) and cerebrospinal fluid (CSF) examination 
by one examiner (S.T.F.M.F.) in order to prevent interrater variability (Goodkin et ál., 
1992). He was blinded to the PB and CSF findings. A change of one EDSS-point or more 
was considered to reliably detect a change in clinical activity (Noseworthy et al., 1990). 
The relapse rate/patient and a baseline-EDSS were determined retrospectively for the year 
preceding the initial IVMP treatment. A relapse was defined as a symptomatic 
deterioration with the occurrence of one or more new symptoms lasting less than 8 weeks 
but longer than 24 hours without subsequent spontaneous improvement. 
PB and CSF. PB and CSF samples were drawn according to standard procedures. CSF 
analysis included mononuclear cell count, albumin-quotient (Q-albumin), IgG index, 
intrathecal IgG synthesis, number of oligoclonal bands on isoelectric focusing, and CSF 
MBP. IgG and albumin were measured in unconcentrated CSF and diluted serum (1:400) 
by means of an automated kinetic nephelometric method. Sheep antihuman IgG 
(Boehringer, Mannheim, FRG) and rabbit antihuman albumin (Behringwerke AG, 
Marburg /Lahn, FRG) were used. Q-albumin was defined as CSF albumin/PB albumin. Q 
IgG was calculated with the same equation. IgG index was defined as Q IgG/Q albumin. 
The calculation of intrathecal IgG synthesis (intrathecally produced IgG) was performed 
according to the hyperbolic Reiber formula (Reiber and Felgenhauer, 1987). For iso-
electric focusing (IEF) paired CSF and PB examinations were performed with ready made 
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LKB Ampholine PAG plates (productor. 1804-101, pH range 3.5-9.5) and Coomassie 
blue staining. Myelin basic protein (MBP) was determined according to the instructions of 
the manufacturer (Diagnostic Systems Laboratories, Webster Texas USA, cat.nr. 1500), 
using a double antibody radioimmunoassay kit containing human basic protein (whole 
molecule) as antigen and rabbit anti-human MBP as anti-serum. Goat anti-rabbit gamma 
globulin was used as MBP precipitation reagent. Human MBP (J,2S 2μ(1ϋ/νΐ3ΐ) was 
included in the test kit. The detection limit was 0.1 Mg/l; the variation coefficient of the 
assay was 7.5%. The reference values for the CSF variables were determined in a group 
of 35 patients (18 females, mean age 41 years, range 15-66 yrs.; 17 males, mean age 45 
years, range 17-65 yrs.) with psychoneurosis without evidence of any organic, infectious 
or auto-immune inflammatory neurologic disease. 
Statistical analysis. Data before and after treatment and after the follow-up period were 
compared by means of a Wilcoxon matched-pairs signed rank test. Differences between 
the three disease courses were analysed by means of the Kruskall-Wallis test and the Chi-
square test. Null-hypotheses were tested two-sided, and ρ values smaller than 0.05 were 
considered statistically significant; ρ values between 0.05 and 0.10 were considered as 
trends. 
Results 
The pre-treatment data are shown in Table 1. Age at entry (p = 0.0311), disease duration 
(p = 0.0482), and baseline EDSS (p = 0.0005) were significantly different in the three 
disease courses. Mean follow-up period after entry was 2.6 years (range 1.7- 3.5 yrs.). 
The total number of additional IVMP treatments during the follow-up period was 59 
(range 0-5/ patient); 10 patients had no repeated IVMP and 8 patients received IIS during 
the follow-up. 
IVMP was well tolerated and the adverse effects were generally mild. Three major 
incidences occurred after 105 IVMP courses (3%): 1 IVMP recipient developed an 
epileptic seizure, an other patient had an exacerbation of chronic bronchitis, and one 
patient developed a peptic ulcer. 
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The number of repeated IVMP treatments was independent of the disease course (Chi-
square = 2.6, df=4, not significant; Table 2). Mean relapse rate/patient/year in the year 
before IVMP was 2.6 in the RR and CP+RR MS patients (N = 38; not in table); during 
the follow-up period there was a significant (p< 0.0001) reduction to 0.8 in the relapse 
rate/patient/year in the same patients. 
The changes of the EDSS scores after IVMP are mentioned in Table 3 and Figure 1. 
Sixty-five percent of the 46 MS patients (30/46) showed a clinically significant decrease 
in the EDSS (1.0 point or more) after the first IVMP therapy; this was independent of the 
disease course of the individual MS patient. The percentage for the CP group was 63% 
(12/19), the RR group 68% (13/19), and for the CP+RR group 63% (5/8). No patient's 
situation worsened during the first IVMP treatment. 
Table 1. Pre-treatment data of the study groups. 
Men/women 
Age at entry (years) 
Disease Duration 
Baseline EDSS 
Progression Rate 
Chronic Progressive 
(CP) (N=19) 
9/10 
40.3 (25-55) 
9.3 (1-22) 
4.1 (3.0-8.0) 
1.0(0.1-6.0) 
Relapsing-Remitting 
(RR) (N=19) 
6/13 
34.0 (22-57) 
4.6 (0-19) 
1.7 (1.0-9.0) 
1.1 (0.1-10.0) 
Chronic Progressive 
with Relapses 
(CP+RR) (N=8) 
2/6 
35.9 (2444) 
4.7 (0-7) 
3.2 (3.0-7.0) 
0.7 (0.2-1.5) 
Legend: EDSS=Expanded disability Status Scale; Progression Rate= EDSS/DD; Mean and range 
are mentioned. 
At the end of the follow-up period 19 patients (41%) showed an increase of the EDSS-
rating of 1.0 point or more in comparison to the EDSS-rating just after the first IVMP 
course; 22 patients (48%) had no changes in the EDSS-rating, and 5 patients (11%) 
showed a clinical improvement (1.0 point or more decrease on the EDSS). In the CP MS 
patients clinical decline (increase of the EDSS rating of 1.0 point or more) during the 
follow-up was highest: 58% of the CP MS patients (11/19) showed an increase of the 
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EDSS score, followed by the CP+RR MS group (37.5%; 3/8); clinical deterioration was 
lowest for the RR MS group (26%; 5/19). During the follow-up period 16 patients 
(16/27; 59%) of the relapsing (RR and CP+RR) MS patients remained clinically stable 
and 3 patients (3/27; 11 %) showed a clinical improvement. In the CP MS group only 6 
patients (32%, 6/19) showed no clinical deterioration and 2 patients (10%, 2/19) 
improved. Comparing the baseline EDSS and the EDSS ratings after the follow-up period 
(Table 3), the CP MS group showed a trend (p= 0.0522) towards an increase in the mean 
EDSS (4.6 versus 4.1); when the entire CP MS group (CP and CP+RR) was taken the 
difference (4.6 versus 3.8) was statistically significant (p< 0.05); in the RR MS group 
the difference was not statistically significant. For the entire MS group the increase in 
EDSS ratings after the follow-up period (3.7 versus 2.9) was statistically significant (p< 
0.01). In Table 4 the MS patients who received IVMP only during the follow-up are 
analysed apart from the MS patients treated with intensive immunosuppression (IIS) 
(N=8). The 10 MS patients who had no repeated IVMP course, were all clinically stable 
during the follow-up period. 
Table 2. Number of patients treated with a repeated course of high-dose intravenous methyl-
prednisolone (IVMP) or an other regimen during the follow-up period according to the course of 
disease. 
Chronic 
Progressive 
(CP) 
Relapsing-
Remitting 
(RR) 
Chronic 
Progressive 
with Relapses 
(CP+RR) 
Total 
No other course 2 
1 repeated IVMP 8 
¿2 repeated IVMP 5 
Other treatment 4 
7 
6 
4 
2 
10 
16 
12 
8 
Legend: Other treatment was intensive immunosuppression (IIS) with cyclophophamide/predni-
sone. Five patients treated with IIS received more than 1 IVMP course during the follow-up 
period; the other 3 patients with IIS received directly after the first IVMP treatment IIS. 
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Table 5 displays the PB and CSF examinations before and after the first Г МР therapy 
and after the follow-up period. Before IVMP no significant differences were found 
between the three disease courses for the PB and CSF variables. Except for Q albumin 
and PB IgG, all CSF variables before treatment were significantly increased compared to 
the reference levels. The CSF variables (except Q albumin) decreased significantly after 
IVMP; during the follow-up period all the CSF levels showed a slight increase but not a 
statistically significant one in comparison with the levels directly after the first IVMP 
treatment. 
Table 3. Mean EDSS ratings in 46 MS patients before and after the first treatment with high-dose 
intravenous methylprednisone (IVMP) and after the follow-up period. 
EDSS 
Chronic 
Progressive 
Relapsing-
Remitting 
CP+ RR 
Baseline ρ Value Before ρ Value After ρ Value Follow-
EDSS IVMP IVMP up 
4.1 
1.7 
3.2 
0.00000 5.2 
0.0312 5.0 
0.00049 4.0 
0.00000 3.2 0.00024 1.9 
0.06250 4.3 
0.01660 4.6 
ns 
ns 
2.4 
4.4 
Total 2.9 0.00000 4.3 0.00000 3.2 0.0066 3.7 
Legend : Statistical analysis (Wilcoxon's signed rank test) is performed between the baseline 
EDSS ratings (1 year before the initial IVMP) and EDSS ratings directly before the initial Г МР, 
between before and after the initial IVMP course and between the EDSS ratings directly after the 
first IVMP course and after the follow-up period. 
However, the CSF MBP level decreased further significantly. All CSF levels were 
statistically (p< 0.05) lower compared with the levels just prior to the first IVMP course; 
the levels, except for Q albumin and PB IgG, were not normalized with respect to the 
reference values. Statistically there were no significant differences in the CSF variables 
after the follow-up period between the MS patients treated with 1 IVMP course only, and 
the patients who received more than 1 IVMP course during the follow-up period. No 
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correlations could be obtained between the changes of CSF variables and the clinical 
course during the follow-up period. 
Table 4. Mean EDSS ratings in 46 MS patients before and after the first treatment with high-dose 
intravenous methylprednisolone (IVMP) and after the follow-up period according to the kind of 
treatment received during the follow-up period. 
EDSS Baseline ρ Value Before ρ Value After ρ Value Follow-
EDSS IVMP IVMP up 
IVMP (N=38) 2.7 
*no repeated 2.8 
IVMP (=10) 
•repeated 2.7 
IVMP (n=28) 
0.00000 4.3 0.00000 3.1 
0.0156 3.9 0.0074 3.1 
0.00000 4.4 0.00045 3.0 
0.02313 3.4 
ns 3.1 
HS (N = 8) 3.9 0.0626 4.6 ns 3.8 
0.02 
ns 
3.5 
5.0 
Legend : IIS= intensive immunosuppression (cyclophosphamide/prednisone). Statistical analysis: 
see Table 3. 
Discussion 
Whether high-dose intravenous methylprednisolone (IVMP) treatment influences the 
natural course of multiple sclerosis (MS) or not is not known. Whitham and Bourdette 
(1989) have reported on twenty-three MS patients treated with IVMP pulse therapy 
receiving four-weekly infusions for one year. In chronic progressive MS patients no 
beneficial clinical effect was found compared with the pretreatment disease course but in 
relapsing MS patients a reduction in the relapse rate was noted. In our longitudinal 
prospective study with a mean follow-up of 2.6 years, we have studied 46 MS patients 
treated with Г МР. In addition the effect of IVMP on PB and CSF variables was 
determined. 
Clinically, expressed by Kurtzke's EDSS, after the first IVMP course all three MS groups 
showed a reduction in the EDSS ratings compared with the pretreatment level. After the 
follow-up period, a significant increase was noted for the EDSS ratings in the chronic 
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progressive (CP) MS group, but not for the patients with relapsing MS disease. In MS 
patients with progressive disease (CP and CP+RR), treated with Г МР or intensive 
immunosuppression, our study has shown a mean progression rate of 0.3 EDSS point per 
year (baseline EDSS 3.8 versus 4.6 after the follow-up period). In comparison with the 
findings about the natural course and prognosis of multiple sclerosis by Weinshenker et 
al. (1989) and Confavreux et al. (1980), who reported a mean rate of deterioration of 
0.33-0.50 EDSS point per year in untreated patients with (progressive) MS, the mean 
EDSS changes per year in our study is broadly the same. This means that in progressive 
MS disease (repeated) IVMP treatment is not successful in the long term. 
EDSS 
6 
5.5 
5 
4.5 
4 
3.5 
3 
2.5 
2 
1.5 
1 
0.5 
0 
Chronic 
progressive (CP) 
Relapsing-
Remittìng (RR) 
• Baseline * Pre IVMP • Post IVMP • Follow-up 
8 9 10 11 12 
Disease duration (years) 
Figure 1. The changes in the mean EDSS ratings indexed to the disease duration in 46 
MS patients treated with (repeated) IVMP and separated for the various disease courses. 
Baseline= baseline-EDSS; Pre/post IVMP= EDSS just before and after the first IVMP 
treatment; follow-up = follow-up EDSS. 
In the relapsing (RR and CP+RR) MS patients, a significant decrease occurred in the 
relapse rate/patient/year during the follow-up period in accordance with Whitham and 
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Bourdette (1989). Although clinical decline is not prevented or stopped, it seems that 
there is a favourable clinical effect in the long term in relapsing MS disease. It is clear 
that during the follow-up the most worsened MS patients are selected for a more 
aggressive therapy (IIS), so from this study it is not possible to decide whether (repeated) 
IVMP treatments decrease clinical decline/deterioration in MS or not. A double-blind 
(placebo) controlled study with a long follow-up period would be necessary to bring a 
deeper understanding, although this might be ethically difficult to perform. 
In this study IVMP courses usually were well tolerated and the small number of adverse 
effects (3%) were generally mild. Fractures due to steroid-induced osteoporosis during the 
follow-up period did not occur. Troiano et al. (1992) observed that fractures in MS 
patients are significantly more common during the steroid period. Lyons et al (1988) 
showed no increase of fractures in MS patients treated with high-dose intravenous 
steroids. 
In our study, all CSF variables (mononuclear cell count, MBP, IEF, IgG) showed a 
significant decrease in comparison to the levels before the first IVMP treatment. This is 
in accordance with other studies (Tourtellotte et al, 1982; Tourtellotte et al., 1980; 
Compston et al, 1987; Baumhefner et al., 1989; Warren et al, 1987; Warren et al., 
1986; Frequin et al, 1992). After the follow-up period we found persistent and prolonged 
decreased levels of the CSF variables in comparison with the pre-treatment levels. Only 
peripheral blood PB IgG showed a significant increase during the follow-up. Prolonged 
effects of reduced inflammation (decrease of the CSF mononuclear cell count and 
intrathecal IgG synthesis) and decreased myelin breakdown (decrease of CSF MBP) seem 
to be present in MS patients 1.6 years after the initial course with IVMP. These effects in 
the CSF were independent of the number of IVMP treatments during the follow-up 
period. Because at the moment there is no curative therapy in MS, it is important to know 
that IVMP also seems to have prolonged beneficial effects on various CSF variables.lt 
would be interesting to see if there are persistent effects on MRI of the brain in MS 
patients after IVMP. Long-term effects of IVMP in MS patients on MRI lesion-load or 
contrast-enhancement have not been studied. Miller et al (1992) reported a limited 
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duration of effect after IVMP on gadolinium-enhanced MR in MS patients. Using 
unenhanced T2-weighted MR images only, however, no normalisation of the signal 
intensity is found, which indicates persistent tissue alterations directly after IVMP 
treatment. Whether these T2-abnormalities will eventually resolve is unknown. Further 
MR studies should also focus on the question whether new MR abnormalities are 
prevented. 
In conclusion, our study is the first study which assesses the long-term effects of IVMP in 
MS. In MS, IVMP treatment seems to reduce the relapse rate in relapsing MS patients, 
although clinical decline expressed by increase in the EDSS rating during the follow-up 
period is not prevented. In MS patients with chronic progressive disease no decrease of 
clinical deterioration could be found after (repeated) IVMP in comparison with the natural 
course. Two years after IVMP treatment prolonged effects (decreased intrathecal IgG 
synthesis, CSF MBP) are found in the CSF of MS patients. More study, e.g. with 
gadolinium-enhanced MRI during the follow-up period, is needed to further assess the 
long-term effects of IVMP in relapsing and chronic progressive MS patients. 
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CHAPTER 9 
LIMITED DURATION OF THE EFFECT OF METHYLPREDNISOLONE ON MR 
IMAGING IN MULTIPLE SCLEROSIS 
F. Barkhof, M.W. Tas, S.T.F.M. Frequin, P. Scheltens, O.R. Hommes, J.J.P. Nauta, 
J. Valk 
(Submitted for publication) 

Methylprednïsolone/ MRI follow up in MS 
Introduction 
Magnetic resonance (MR) imaging in multiple sclerosis (MS) frequently detects silent new 
disease activity, and is therefore well suited to evaluate the effect of therapy (Miller et 
al, 1991). Corticosteroid treatment is frequently given to decrease the severity and 
shorten the duration of relapses in MS (Thompson et al., 1989; Milligan et al, 1987; 
Durelli et al., 1986). Recent studies have shown that intravenous (IV) methylprednïsolone 
treatment reduces gadolinium (Gd) enhancement, while no significant effect is observed in 
the corresponding abnormalities on T2-weighted images (Barkhof et al, 1991; Bumham et 
al., 1991; Miller et al., 1992). This implies that methylprednïsolone selectively 
suppresses the inflammatory component of lesions, which is accompanied by blood-brain 
barrier disruption. 
The purpose of this study is to evaluate disease activity assessed by MR imaging 
following methylprednïsolone treatment, to see whether I) the suppression of Gd-
enhancement is permanent (or re-enhancement occurs), II) the development of new (Gd-
enhancing) lesions is suppressed (and if so, for how long), and III) whether any changes 
occur in the course of time on T2-weighted images in the abnormalities corresponding to 
areas of previous Gd-enhancement. 
Patients and methods 
Thirteen patients with clinically (n=ll) or laboratory supported (n=2) definite MS (Poser 
et al., 1983) and a relapsing-remitting disease course were prospectively studied. The 
mean age was 28 (range 21-40). Most patients had a short (mean 3.1 yrs, range 0.5-13 
yrs) disease duration, and had a relatively moderate disability (median baseline EDSS 2.S, 
range 1.5-5). All patients but one had oligoclonal IgG bands in their CSF on iso-electric 
focusing. 
Patients entered the study at the time of an acute clinical relapse (development of new 
symptoms or worsening of old symptoms for at least 24 hours, not related to a period of 
fever or concurrent disease), for which high-dose IV methylprednïsolone treatment was 
given (1000 mg/day for 10 days). Throughout the study, clinical evaluation and MR 
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scanning were performed at the same moment, i.e. before and after methylprednisolone 
therapy and then at monthly intervals. When new clinical relapses occurred, treatment 
was repeated. The study period for individual patients varied between 19 and 83 weeks 
(mean SO). All patients gave informed consent after the nature of the study had been fully 
explained. Clinical disability was assessed by means of the Expanded Disability Status 
Scale (EDSS) (Kurtzke, 1983). The duration of effect on clinical grounds was defined as 
the period between the end of the treatment and the occurrence of clinical signs or 
symptoms, leading to an increase in EDSS (clinical activity). 
MR imaging was performed on a 0.6 Tesla system (Technicare Solon, Ohio), using a 
standard head coil. Throughout the study, a standard imaging protocol was employed. To 
assure acceptable section reproducibility (irrespective of the patients position in the 
scanner), we used 2 consecutive scout images (coronal, sagittal), the oblique scanning 
facility and internal landmarks of the brain. Axial (double oblique) series were made 
according to internal landmarks (caudal borders of the pituitary gland and the fastigium of 
the 4th ventricle for angulation; caudal border of the splenium of the corpus callosum as 
Z-centre). This procedure secures a reasonably small angulation error in serial studies 
(Barkhof et al, 1992c). T2-weighted spin echo images (2755/ 60,120(reduced bandwidth)/ 
2) [TR/ТЕ /excitations] were obtained precontrast. Gd-DTPA (Schering AG, Berlin) was 
administered IV in a dose of 0.2 mmol/kg, followed by a post-injection flush with 10 cc 
saline. T,-weighted spin echo sequences were obtained (400/28/4) starting 5-10 minutes 
after Gd injection, with an in-plane resolution of 1.0 χ 1.3 mm, and a slice thickness of 5 
mm (gap 1.25 mm). The total investigation time was 45 minutes. Halfway through the 
study, the imaging protocol was adjusted, and Gd was injected prior to the scout images, 
and Τ,-weighted images were then obtained before the T2-weighted series. The latter 
protocol reduces the investigation time to 35 minutes, precludes changes in repositioning 
from table removal for Gd-injection, and doesn't hamper lesion conspicuity on T2-
weighted images (Barkhof et al, 1992b). 
MR images were analyzed by 2 of the authors in conference. The number, not the size, 
of Gd-enhancing lesions was used as study parameter. For all new lesions the location 
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was noted in 7 anatomical regions. We assessed whether areas of enhancement were 
represented by abnormalities on T2-weighted images. In addition we looked for new not 
enhancing lesions. On each follow-up image, we analyzed whether 1) lesions persisted or 
had ceased to enhance, 2) new areas of enhancement had occurred, 3) new not enhancing 
lesions had occurred, and 4) whether lesions changed in size in the course of time on T2-
weighted images. Although meticulous efforts were performed to assure reproducible 
slicing, slight changes in slice positioning inevitably occurred, due to hardware and 
patient limitations. As a consequence, lesions sometimes changed in appearance as a 
result of (changes in) volume averaging. Changes in appearance were therefore only 
registered, when marked changes in size occurred; disappearance of lesions (beyond the 
scanner resolution) was assumed when a lesion was not visible on two consecutive 
images. 
Not only enhancing lesions (either new areas of enhancement, reenhancement of 
previously enhancing areas and persistently enhancing areas), but also new nonenhancing 
lesions, and enlarging lesions without enhancement were considered as lesions showing 
disease activity, and together were called "active" lesions. The duration of effect of 
methylprednisolone on the development of active lesions on MR imaging was defined as 
the period between the end of the therapy and an increase in the number of active lesions 
(MR activity). 
Results 
Clinical. Four patients did not suffer from a new relapse duirng the study period and 
therefore were treated only once at the beginning of the study. All the other patients 
suffered from new clinical relapses, for which they received additional courses of 
methylprednisolone during the study period: 4 patients one, 2 patients 2, 2 patients 3, and 
1 patient 4. A total of 31 courses of methylprednisolone were thus given. One patient was 
treated twice at the time of development of numerous new MR lesions, although she had 
minimal accompanying clinical signs or symptoms at that time. Of the 29 courses of 
methylprednisolone treatment given on clinical grounds, clinical improvement was 
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Figure 1. (A-J) Sequential MR images of patient 7 (see also Figure 2A) showing adequate 
slice repositioning. (Α-F) MR images at level of basal ganglia. (A) T2-weighted MR image 
obtained at the time of a clinical relapse just before 4th course of methylprednisolone (see 
Figure 2A) shows multiple (periventricular) lesions with high signal. (B) Corresponding 
T,-weighted MR image shows that only 2 lesions are active and enhance with Gd. A total 
of 8 active lesions is detected on this month's scan. (C-D) MR images obtained during 
clinical remission after methylprednisolone treatment four weeL· later, showed complete 
suppression of enhancement (D), but unaltered abnormalities on T2-weighted image (C). 
(Ε-F) Again 9 weeks later, 3 Gd-enhancing lesions are visible (F), two of which (frontal 
horn right side and internal capsule left side) are reactivated lesions ( already visible on 
prior Tfweighted images), while 1 new lesion has emerged in left parietal lobe, and is 
visible on the T2-weighted scan (E). A total of 10 active lesions is detected on this month's 
scan. The increase in MR activity ("MR relapse") occurs while the patient still is 
clinically stable, and about 10 weeks before a new clinical relapse occurs. (G-J) MR 
images at level of centrum semi-ovale. T2-weighted MR image obtained at the same time 
as (Α-B) shows multiple (confluent) high signal lesions (G), none of which enhances with 
Gd (H). Four weeks later (compare C-D), T2-weighted MR image is unaltered (I), while 
T
r
weighted image reveals 2 new areas of enhancement (J); this activity would have been 
missed without Gd administration. 
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observed after 26 (90%) courses, consisting of a decrease in EDSS of 0.5 in S courses 
(18%) and of 1.0 or more points in 21 courses (72%). 
MR imaging. We observed that even with optimal slice repositioning, it is sometimes 
difficult to detect all changes on the T2-weighted images, and that Gd-enhancement greatly 
facilitates this. In some cases new activity would have been missed completely on 
sequential T2-weighted images, especially when new areas of enhancement occurred 
amidst confluent areas of abnormalities on the Trweighted images or when reenhance-
ment occurred (Figure 1). 
During the study 195 MR examinations were performed (range, 7-24 per patient) and a 
total of 549 new Gd-enhancing lesions were detected (in case an enhancing lesion was 
seen on the first scan, it was assumed it was new), 55 of which were not seen on the 
corresponding T2-weighted images (mean 41 per patient; range, 1-105); in addition, 18 
new nonenhancing lesions (3% of all new lesions) in 7/13 patients, and 4 enlarging 
lesions without enhancement (enlargement occurred far more often, but was usually 
accompanied by Gd-enhancement) were observed. Reenhancement occurred in 38 lesions 
in 10/13 patients: in 12 lesions re-enhancement occurred on the second or third MR 
examination after treatment (i.e. 1 or 2 months after treatment), in 26 lesions independent 
of treatment (Figure 1). Thus, a total of 609 active lesions were detected during the 
study, 93 (15%) of which would have been missed without Gd-enhancement. Most of the 
new lesions (n=543, 96%) were located supratentorially. Of those lesions the majority 
(n=365, 64%) was located in the deep white matter; 15% were related to gray matter 
structures (cortex, junction of cortex and white matter, or basal ganglia) (Table 1). 
Before all 31 courses of treatment, 293 "active" lesions were found. A decrease in the 
number of active lesions was seen after all courses but one (second course in patient 12). 
After treatment 229 (78%) of these were not active any more, while 17 new nonen-
hancing lesions were detected and 1 lesion enlarged without enhancement. Thus, 82 active 
lesions were seen after treatment. The percentage of decrease in the number of active 
lesions before treatment ranged from 0-100% for the individual courses. The percentage 
of decrease, averaged per patient, ranged from 35 to 100%, with a mean of 78%. 
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The mean time interval between the pretreatment and posttreatment MR scan was 22 days 
(SD 12 days). The last two courses in patient 11, which were administered on the basis of 
an increase in the number of active MR lesions, led to complete suppression of 
enhancement directly after treatment, but one month later a return to the pretreatment 
number of active lesions was observed. 
Of all 567 new lesions (both enhancing and nonenhancing), 103 (18%) eventually 
disappeared on the T2-weighted images. Of the new lesions, that were first seen directly 
before methylprednisolone treatment was initiated (n=357), 87 (24%) eventually 
disappeared. Because lesions that developed before treatment had a longer follow-up 
period than lesions that developed after treatment, the lesions that were first seen on the 
pretreatment scan presumably had the same disappearance rate as those lesions seen to 
develop after treatment. Lesions that persisted on follow-up T2-weighted images 
frequently became confluent with préexistent T2-abnormalities, or could not individually 
be identified in the first place. 
Clinical and MR imaging correlation. Figure 2 displays for patients 7,8,9 the relation 
between the number of active lesions and the EDSS score as a function of time. The 
timing of methylprednisolone courses is indicated by arrows. 
After 2 courses of methylprednisolone no adequate follow-up was available (last courses 
in patients 7 and 8). Only after one course (patient 10) the clinical effect was shorter than 
the MR effect (although the MR was never completely negative after methylprednisolone), 
while after three courses (patient 2, 6, and 13) neither clinical nor MR activity was 
detected before the end of the follow-up period. In most courses (89%), however, the 
effect on MR lasted for a shorter period than the clinical effect (Figures). Actually, after 
11 courses new MR activity was detected without any new clinical activity during the 
follow-up period, whereas after the 12 courses in which any new clinical activity was 
detected, active MR lesions were detected before new clinical activity was observed 
(Figure 2). 
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Table 1. Distribution of (549 enhancing and 18 nonenhancing) new lesions. 
location 
supratentorial 
periventricular 
cerebral cortex 
junction cortex/white matter 
deep white matter 
frontal lobe 
parietal lobe 
occipital lobe 
temporal lobe 
internal capsula 
basal ganglia 
infratentorial 
brainstem 
cerebellum 
total 
number of le 
92 (16%) 
29 ( 5%) 
44(8%) 
213 (38%) 
73 (13%) 
24 ( 4%) 
51(9%) 
4(1%) 
13(2%) 
11 (2%) 
13(2%) 
567 (100%) 
The effect of methylprednisolone treatment showed a mean duration of 9.7 weeks with 
regard to the suppression of active MR lesions, while the clinical effects lasted 17.1 
weeks. Thus, MR showed new activity on average 7.4 (43%) weeks earlier than new 
clinical activity was recorded; probably, this percentage is -an underestimation, as in all 
but two courses new MR activity was detected before the end of the follow-up, while 
after most courses no new clinical activity had been detected during the follow-up. In 
other words, with regard to new clinical activity, the observation time had been censored. 
The actual duration of the clinical effect can be estimated statistically by a method called 
maximum likelihood estimation for censored observations (Cox and Oaks, 1984). As­
suming that the distribution of the duration of the clinical effect is approximately 
Gaussian, the actual average duration of the clinical effect can be estimated at 20.3 
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weeks, indicating that the MR effect lasted 10.6 weeks (52%) shorter on average. A 
Kaplan-Meier curve (Figure 3) shows that the percentage of patients free from disease 
activity is clearly lower if assessed by MR then by clinical examination. 
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Figure 3. Kaplan-Meier curve shows percentage of patients free of disease activity versus 
time on clinical grounds and on MR grounds. Note that the percentage of patients free of 
new MR imaging disease activity decreases more rapidly than the percentage of patients 
free of new clinical disease activity. 
Discussion 
Corticosteroids and most other drugs to treat MS, are used because of their immuno-
suppressive effect. As blood-brain barrier disruption in MS indicates active inflammation, 
Gd-enhancement is well suited to monitor immunosuppressive treatment , such as methyl-
prednisolone treatment. In addition to enhancing lesions, in the present study the group of 
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"active" lesions also included new or enlarging nonenhancing lesions. The rationale for 
doing so, is that such lesions represent progression of the disease, even in the absence of 
(detectable) blood-brain barrier disruption. By combining enhancing and nonenhancing 
active lesions, every type of progression of the disease on MR is included (96% of active 
lesions enhanced). 
The beneficial clinical effect of methylprednisolone on the short-term is well established 
(Thompson et al., 1989; Milligan et al., 1987; Durelli et al., 1986), and methylpred-
nisolone is widely used to shorten the duration and reduce the intensity of relapses in MS. 
The beneficial short-term clinical effect of methylprednisolone is associated with an 
improved integrity of blood-brain barrier (Barkhof et ai, 1991; Bumham et al., 1991; 
Miller et al., 1992; Troiano et al., 1984). It has been shown that a correlation exists 
between clinical improvement, suppression of Gd-enhancement and demyelination 
(Barkhof et al., 1992a). It therefore may be assumed that restoration of the blood-brain 
barrier plays an important role in clinical improvement, by reducing cellular infiltration, 
edema, entrance of cytokines or complement (Miller et al., 1992), or by reducing 
demyelination (Barkhof et al, 1992a). Whether methylprednisolone has any beneficial 
effect on the clinical course in the long-term is at least debatable (Menken, 1989; Goodin, 
1991; Compston, 1988). In the present study, serial MR imaging shows that the effect of 
methylprednisolone treatment is temporary and probably will have little long-term effect. 
This is illustrated by the following observations. 
The suppression by methylprednisolone of Gd-enhancement seen pretreatment, seems to 
be more or less permanent as re-enhancement occurred infrequently with the presently 
used dose (1 gram for 10 days): in only 12 out of 293 active lesions (4%) seen before 
treatment. If a lower dose of methylprednisolone is used (1 gram for 3 days) re-
enhancement might occur more often (39%) (Miller et al., 1992), although the timing of 
the treatment and scanning in that study are not quite comparable to those in the present 
study. Unfortunately, the rather effective suppression of Gd-enhancement does not lead to 
a increased disappearance of related abnormalities on T2-weighted images, if compared to 
the disappearance rate of lesions that developed after treatment or if compared to the 
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naturai disappearance rate in studies of untreated patients (Barkhof et al., 1992c; 
Thompson et al., 1992). Thus, although inflammation is suppressed, the vast majority of 
lesions show persistent T2-abnormalities at follow-up. Apparently, the temporary opening 
of the blood-brain barrier has already caused considerable tissue changes (e.g. edema, 
cellular infiltration and demyelination). Or, alternatively, the suppression of Gd-
enhancement is the result of reduced cytokine production by inflammatory cells, while the 
inflammatory process inside the blood-brain barrier continues to damage myelin. 
The most important reason to conclude that there is no long-term effectiveness of 
methylprednisolone treatment is that an increase in new lesions ("MR relapse") occurs at 
some stage in most patients after cessation of methylprednisolone therapy. If there was 
sufficient follow-up time, after all courses but one, new MR activity preceded new, if 
any, clinical activity. MR showed an average reduction in duration of effect of 5296 
compared to clinical criteria. The reduction in the percentage of patients free from disease 
activity on MR imaging as compared to the clinical disease activity is illustrated by the 
Kaplan-Meier curve (Figure 3). One could argue that the effect of methylprednisolone 
could be prolonged by either adding an oral tapering regimen, or by prophylactic 
intravenous pulse doses, given monthly (Whitham and Bourdette, 1989; Polman et al., 
1991). 
What then is the clinical implication of new clinically silent brain MR lesions? First, 
disability shows varying but usually positive relation with overall extent of MR 
abnormalities according to a review by Wallace et al. (1992). A more closer correlation 
can be observed for individual symptom scores with specific brain areas (Truyen et al., 
1990). Second, follow-up revealed a significantly higher number of new MR lesions in 
patients showing relapses than in those without (Truyen et al., 1991). Apparently, not all 
new brain MR lesions increase clinical disability, as they are located at nonstrategic sites 
(but do correlate with neuropsychologic impairment (Rao et al., 1989)). The EDSS, for 
example mainly evaluates motor function, which probably best correlates with the 
presence of spinal lesions. Third, postmortem MR findings correlate well with 
pathological findings, indicating that brain MR lesions represent the demyelinated plaques 
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characteristic of MS (Stuart et al., 1984; Nagara et al., 1987). (Interestingly, Lumsden 
(1970) notes a poor correlation of pathological findings with the clinical picture). In 
conclusion, new brain MR lesions indicate progression of the disease, although their exact 
relation to clinical disability remains to be elucidated. The finding, in the present study, 
of MR relapses relatively soon after cessation of methylprednisolone treatment, indicates 
clinically silent, but nevertheless significant progression of the disease. 
Serial MR studies frequently detect clinically silent disease activity in relapsing-remitting 
MS patients (Miller et al., 1991). Therefore, the criteria in this study for the duration of 
effect of methylprednisolone on MR images have been rather strict, as it was defined as 
the disease-free period before an increase in the number of active lesions ("MR relapse"). 
After 7 courses, however, the MR image was never without active lesions, although 
fewer lesions were seen than before treatment. If any new clinical activity was detected at 
all, it was usually preceded by an increase in MR activity. Apparently, an increase in MR 
disease activity only leads to a clinical worsening if enough active lesions are present, or 
if active lesions develop in strategically important locations (e.g. internal capsule, 
brainstem, cerebellum, or spinal cord). These observations underline the capabilities of 
serial MR imaging in assessing disease activity. 
One should keep in mind that most relapses are self-limiting anyway and that after an 
exacerbation a remission phase will set in by definition in relapsing-remitting MS 
patients. 
Perhaps methylprednisolone is even less effective then we believe it is; in two courses not 
administered on clinical grounds, but because an increase of enhancing lesions was 
observed, the effect of methylprednisolone was extremely short. If we accept that MR 
activity and clinical activity are comparable measures of disease activity in MS, then this 
observation shows that disease activity is actually tempered for a very short time only, 
and that clinical improvement in most cases will be the result of (acceleration of) the 
natural course. It would be of particular interest to study in a placebo-controlled fashion 
whether steroids, not administered on clinical grounds, but on MR grounds, could alter 
the evolution of the MR pattern and subsequently the clinical pattern. 
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CHAPTER 10 
SUMMARY AND CONCLUSIONS 

Summary and conclusions 
Summary and conclusions 
The general aim of this thesis is to gain more insight into the mechanisms and the mode 
of action of high-dose intravenous methylprednisolone (IVMP) treatment in multiple 
sclerosis (MS) patients. Chapter 1 gives a short general survey on MS, its diagnosis, 
pathology, etiology, and applied treatments. Since the 1980s IVMP therapy has been 
introduced for the treatment of relapsing and progressive MS. 
In Chapter 2 the effects of IVMP on myelin basic protein (MBP) and IgG and IgM levels 
in the cerebrospinal fluid (CSF) and peripheral blood (PB) of MS patients are discussed. 
One hundred and one patients (62 females; 39 males) with definite MS were treated 
intravenously with 1000 mgr methylprednisolone (MP) for 10 consecutive days. 
Immediately before and after MP treatment clinical scoring (Kurtzke's Expanded 
Disability Status Scale) and cerebrospinal fluid (CSF) analysis were performed. Before 
MP treatment CSF MBP, IgG and IgM immunoglobulin levels (CSF Ig, index and 
intrathecal synthesis) were significantly elevated. The mean CSF MBP levels were 
significantly higher in the relapsing-remitting (RR) and chronic progressive MS patients 
with relapses (CP+RR) than in the CP group without a RR disease course, respectively 
2.1, 2.3 and 1.5 μg/l. A weak positive correlation was found between CSF MBP level 
and EDSS in the RR MS group (r=0.34). CSF MBP was significantly correlated with 
IgM index (r=0.36), IgM synthesis (r=0.26), but not with the IgG levels. Therefore 
demyelination seems to be related to intrathecal IgM production. 
After IVMP treatment mean (median) EDSS decreased from 4.4 (4.0) to 3.3 (3.0). 
Except for Q albumin and IgM index, all CSF immunoglobulin levels decreased 
significantly after MP. The mean CSF MBP returned to reference values. In the RR 
group the decrease in CSF MBP was significantly correlated with the change in EDSS 
(r=0.39). CSF MBP seems to be a good parameter for disease activity in relapsing MS. 
Following treatment CSF MBP was found to be related with the change in IgM index 
(r=0.30). IVMP treatment reduces CSF MBP and intrathecal IgM in a similar way, 
which indicates a relation between these 2 parameters. 
To determine the effects of IVMP on lymphocytes and lymphocyte subpopulations in the 
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cerebrospinal fluid (CSF) and peripheral blood (PB) in MS patients, we studied 67 
patients with definite MS treated with IVMP {Chapter 3). They were classified according 
to the disease course: 32 chronic progressive (CP) patients, 25 relapsing-remitting (RR) 
patients, and 10 patients with a chronic progressive disease course accompanied by 
relapses and remissions (CP+RR). MS patients were treated with 1000 mgr intravenous 
MP daily for 10 consecutive days. Before and after MP treatment we simultaneously 
studied CSF and PB CD3+, CD4+, CD8+, CD20+, and Ial+ cell subsets. Kurtzke's 
EDSS was used for clinical evaluation. Progression rate was defined as the ratio of EDSS 
to disease duration. Thirteen patients with lumbar disk herniation were investigated as 
controls. Before IVMP, we found in MS patients, especially in the CP group, significant­
ly lower CD4+ T-cell percentages in the PB with respect to controls (p<0.05). The 
percentage of CD4+ T-cells in the CSF of MS patients was significantly higher compared 
with PB (p=0.0001), and tended to be higher than in controls (p=0.072). The CSF 
mononuclear cell counts were significantly correlated with higher percentages of CSF 
CD3+ (r=0.40) and CD4+ (r=0.47) T-cells and lower CSF CD8+ (r=-0.33) T-cell 
percentages. B-cell percentages in the CSF were significantly elevated compared with 
controls for all MS groups. No relation could be obtained between T- or B-cell subsets 
and EDSS or progression rate. After IVMP, a significant decrease in PB CD8+ T-cell 
percentage and a simultaneous increase of the percentage CD8+ T-cells in CSF were 
noted in the entire MS group and in the CP and RR MS patients. Except for the CP+RR 
MS patients, CD4+ T-cell percentages in the PB or CSF showed insignificant changes. 
Our findings support the view that in MS IVMP might affect the inflammatory process of 
demyelination by a selective and dissociative effect on T-suppressor/cytotoxic cells in the 
PB and CSF. 
Because several studies have indicated an association between vitamin B12 deficiency and 
MS and a relationship between vitamin B12/folate metabolism and myelination, the effect 
of Г МР was evaluated on these vitamin levels in MS (Chapter 4). Twenty-one patients 
(15 women, 6 men) with definite MS were treated with 1000 mg intravenous methyl-
prednisolone-succinate daily for 10 days. Before IVMP treatment there was a negative 
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correlation (r=-0.59, ρ=0.0084) between serum vitamin B12 and progression rate, defined 
as the ratio of EDSS and disease duration. A significant decrease was demonstrated in the 
CSF and serum levels of folate and in the CSF level of B12 after IVMP treatment. The 
decrease in serum B12 was not statistically significant. After MP treatment all median 
levels of vitamin B12 and folate were below the reference medians. We hypothesize that 
low or reduced vitamin B,2/folate levels found in MS patients may be the result of 
previous corticosteroid treatments. On the other hand, a more causal relationship between 
low vitamin B,2/folate and MS can not be excluded. Further studies may be required to 
clarify the vitamin B12 and folate metabolism in patients with MS. 
Sequential enhanced (with gadolinium-DTPA) MR imaging of the brain frequently shows 
new lesions in MS patients who do not have accompanying clinical signs and symptoms 
(clinically silent new brain lesions). Monitoring of disease activity in MS patients will 
increase in importance as new therapies are developed. We studied sequential enhanced 
MR images of relapsing-remitting MS patients to define the MR features that indicate 
disease activity in this subgroup of patients and to compare MR imaging and clinical 
findings for this purpose (Chapter 5). Seven patients with relapsing-remitting definite MS 
were examined monthly for 4-12 months. A total of 58 unenhanced T2-weighted and T r 
weighted MR images were obtained. MR images showed new enhancing lesions in 6 of 
the 7 patients. On 25(43%) of the 58 enhanced T,-weighted MR images, a total of 50 new 
enhancing lesions were observed, and on 1 image a reenhancing lesion was seen. The 
unenhanced T2-weighted images showed corresponding abnormalities for 92% of the new 
enhancing lesions. In the follow-up, most lesions (86%) were enhanced on only one 
occasion; 4% were enhanced on more than 2 consecutive monthly MR examinations. 
Forty-nine percent of the lesions seen on T2-weighted images "disappeared" (beyond the 
resolution of the imaging system) after a mean follow-up of 3.5 months, especially lesions 
that were initially smaller than 5 mm. During the study, only 5 clinical relapses occurred 
in 3 patients (all at times when MR images showed contrast-enhancing lesions), and fixed 
disability did not increase. On 21 additional occasions, MR images showed new 
enhancing or reenhancing lesions in patients who were clinically stable at the time (4.2 
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times more clinically silent disease activity). The results suggest that contrast-enhanced 
MR imaging is more sensitive than clinical monitoring for detecting new disease activity 
in patients with relapsing-remitting MS, and that MR imaging might be useful in the 
evaluation of therapeutic regimens. 
Chapter 6 and 7 deal with the use of gadolinium-enhanced MR imaging in MS, especially 
in the evaluation of disease activity in MS, and the effect of IVMP on gadolinium-
enhanced MRI. Blood Brain Barrier (BBB) disruption is probably the first event in the 
lesion development in MS. This stage can be visualized by gadolinium-enhanced MR 
imaging of the brain. Serial MR imaging studies have indicated a continuous spectrum of 
disease activity with waxing and waning of acute lesions, even in clinically stable MS 
patients. IVMP has a beneficial clinical effect, reduces gadolinium enhancement indicating 
improvement of the BBB integrity, and decreases intrathecal immunoglobulin synthesis 
with reduction of CSF myelin basic protein (MBP) in MS patients. In a prospective study 
(Chapter 6) we compared the number of Gadolinium-DTPA enhancing lesions on MRI 
with the CSF and clinical findings before and after a total of 20 courses of IVMP in 
relapsing MS patients. Before treatment there was a significant correlation of Gadolinium-
DTPA enhancement (seen on 16/20 scans) and CSF MBP. If enhancement with 
gadolinium-DTPA represents inflammation and CSF-MBP indicates myelin breakdown, 
the amount of inflamed tissue should correlate with the amount of myelin being damaged. 
Clinical improvement occurred following 15/20 courses, and decrease of Gadolinium-
DTPA enhancement in 12/16 scans; the mean CSF-MBP level was the only CSF variable 
to return to reference values. There was a significant correlative triad of decrease in CSF-
MBP, gadolinium-DTPA enhancement and clinical disability. Thus, the clinical effect of 
methylprednisolone might be accompanied by a reduction of inflammation and myelin 
breakdown. A correlative triad is found between gadolinium enhancement, clinical 
improvement, and decrease of CSF MBP following Г МР treatment, indicating a 
relationship between restoration of the BBB integrity, clinical improvement and decrease 
of myelin breakdown. It is not clear whether MP interferes primarily with the process of 
demyelination or reacts non-specifically with its mediators. 
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The last part of this thesis (Chapter 8 and 9) discusses the long-term evaluation of IVMP 
therapy in MS, assessed by long-term MRI follow-up, clinical evaluation, and various 
CSF measurements during the follow-up period. In a longitudinal prospective study 
{Chapter 8), we followed forty-six patients ( 17 men, 29 women) with definite MS, who 
were treated with IVMP for 10 consecutive days with 1000 mg MP a day. Nineteen 
patients showed a chronic progressive (CP) disease course, 19 patients had a relapsing-
remitting (RR) MS disease and 8 patients showed a mixed (CP+RR) disease course. The 
mean follow-up period after entry was 2.6 years (range 1.7-3.5 yrs.). All patients were 
treated because of a symptomatic deterioration. Independent of the disease courses, 65% 
of the 46 MS patients (30/46) showed a clinical improvement after the first IVMP course, 
expressed by a decrease in the EDSS rating (1.0 point or more). During the follow-up 
period 59 additional IVMP treatments (range 0-5 courses per patient) were given; 8 
patients were treated with a combination of cyclophosphamide and prednisone because of 
strong continuous progression. During the follow-up period 19 patients (41%) showed an 
increase in the EDSS-rating (1.0 point or more) compared with the EDSS level just after 
the first IVMP; 22 patients (48%) had no changes in the EDSS-rating, and 5 patients 
(11%) showed a clinical improvement (decrease of 1.0 point or more). In the relapsing 
MS patients (RR and CP+RR, n=38) mean relapse rate/patient/year prior to the first 
IVMP was 2.6, which significantly (p<0.0001) decreased to 0.8 during the follow-up 
period. Statistically no significant difference was found between baseline EDSS and EDSS 
ratings after the follow-up period in relapsing MS patients. In the CP MS patients clinical 
decline (increase of 1.0 point or more on the EDSS) during the follow-up period was 
most prominent: 11 (58%) of the CP MS patients showed an increase of the EDSS-rating, 
followed by 3 (37.5%) of the CP+RR MS group. Clinical deterioration was lowest for 
the RR MS patients (26% ; 5/19). After the follow-up period a significant (p< 0.05) 
increase in the mean EDSS was noted in comparison with baseline EDSS (3.8 to 4.6) in 
chronic progressive MS (CP and CP+RR). The cerebrospinal fluid (CSF) variables (CSF 
mononuclear cells, CSF myelin basic protein (MBP), number of oligoclonal bands on iso-
electric focusing (TEF), IgG index and intrathecal IgG synthesis) decreased significantly 
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after the initial IVMP. After the follow-up period, all variables showed a persistent 
decrease compared with the levels prior to the first IVMP. Our study suggests, that 
(repeated) IVMP reduces the relapse rate in relapsing MS patients, although development 
of disability is not prevented in RR disease. In chronic progressive MS (repeated) IVMP 
does not seem to decrease the clinical deterioration in comparison with the natural course. 
Prolonged effects are found in the CSF of MS patients treated with Г МР, 1.6 years after 
the initial treatment. 
In Chapter 9 we performed serial MR imaging after Г МР treatment to see whether 
suppression of gadolinium-enhancement persists and whether related abnormalities on T2-
weighted images disappear after treatment. Thirteen patients with definite MS received a 
total of 31 courses of methylprednisolone over an average period of 50 weeks. 
Gadolinium enhanced MR scans were obtained before and after treatment, and then at 
monthly intervals, using a standardized slice repositioning and imaging protocol. During 
the study 609 active lesions were detected on a total of 195 scans. Fifteen percent of 
active lesions would have been missed without gadolinium. Directly after treatment the 
reduction in the number of enhancing lesions was 78%, indicating restoration of the BBB 
and suppression of inflammation. In the follow-up, re-enhancement was infrequently 
observed. No beneficial effect on the disappearance rate of related abnormalities on T2-
weighted images was observed, which indicates persistent tissue alteration (e.g. edema, 
cellular infiltration or demyelination). Gadolinium enhanced MR imaging enabled us to 
demonstrate that the duration of the effect of Г МР treatment is temporary (average MR 
effect 9.7 weeks). 
Conclusions 
The treatment of high-dose intravenous methylprednisolone (IVMP) is a safe and 
beneficial therapy in the management of relapsing and progressive MS disease. Г МР 
reduces inthrathecal immunoglobulin synthesis and myelin basic protein in the cerebro­
spinal fluid, and decreases the number of gadolinium-enhancing lesions on magnetic 
resonance imaging. In addition, IVMP seems to have a selective effect on suppressor/ 
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cytotoxic cells in MS. All these mechanisms indicate suppression of the process of 
inflammation and myelin breakdown which is ultimately accompanied by clinical 
improvement. The effects of IVMP treatment on the long-term disease course of MS 
compared with its natural course are less convincing, but prolonged effects of decreased 
inflammation are found in MS patients treated with IVMP. 

CHAPTER 11 
SAMENVATTING EN CONCLUSIES 

Samenvatting en conclusies 
Samenvatting 
Het onderzoek dat in dit proefschrift is beschreven beoogt meer inzicht te geven in de 
mechanismen en de manier van werking van hoge dosis intraveneus methylprednisolon 
(IVMP), toegediend als behandeling bij patiënten met multiple sclerose (MS). 
Hoofdstuk 1 geeft een algemeen overzicht over de ziekte MS, haar diagnose, pathologie, 
etiologie en de meest toegepaste behandelingen. Sinds begin 1980 is IVMP als therapie bij 
de behandeling van exacerberende en progressief verlopende MS geïntroduceerd. 
Hoofdstuk 2 bediscussieert de effecten van IVMP op het myéline basisch proteïne (MBP) 
en de IgG en IgM concentraties in de cerebrospinale vloeistof (CSF) en het perifere bloed 
(PB) van MS patiënten. Honderdenéén patiënten (62 vrouwen, 39 mannen) met definitief 
MS werden behandeld met 1000 milligram methylprednisolon (MP) intraveneus gedurende 
10 opeenvolgende dagen. Onmiddellijk voor en na Г МР behandeling werden de patiënten 
klinisch gescoord (volgens de Kurtzke's Expanded Disability Status Scale - EDSS), en 
analyse verricht van de CSF. Voor de IVMP behandeling waren in de CSF de MBP, IgG 
en IgM concentraties (CSF Ig, index en intrathecale synthese) signifikant verhoogd. De 
gemiddelde CSF MBP concentraties waren signifikant hoger bij exacerberende-
remitterende (RR) en chronisch progressieve MS patiënten met exacerbaties en remissies 
(CP+RR) dan bij de CP MS groep zonder een RR ziekteverloop, respectievelijk 2,1 , 2,3 
en 1,5 μg/l. Een zwakke positieve correlatie werd gevonden tussen CSF MBP en de 
EDSS in de RR MS groep (r=0,34). CSF MBP was signifikant gecorreleerd met de IgM 
index (r=0,36) en de intrathecale IgM synthese (r=0,26), maar niet met de IgG 
concentraties. Derhalve lijkt het zo te zijn, dat demyelinisatie gerelateerd is aan 
intrathecale IgM productie. 
Na de IVMP behandeling nam de gemiddelde (mediane) EDSS af van 4,4 (4,0) tot 3,3 
(3,0). Uitgezonderd voor Q albumine en IgM index werden alle CSF immunoglobuliner 
concentraties signifikant lager na behandeling met IVMP. De gemiddelde MBP 
concentratie in de CSF normaliseerde zich. In de RR groep was de afname in de CSF 
MBP concentratie signifikant gecorreleerd met de verandering in EDSS (r=0,39). CSF 
MBP lijkt een goede parameter te zijn voor de activiteit van de ziekte bij exacerberende 
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MS. De afname in concentratie van CSF MBP na Г МР behandeling was gecorreleerd 
met de afname van de IgM index (r=0,30). Г МР behandeling reduceert de concentraties 
MBP en intrathecal IgM synthese in de CSF in gelijke mate, wat een relatie tussen deze 
twee parameters suggereert. 
Om het effect van IVMP bij MS patiënten op de lymfocyten en lymfocyten subpopulaties 
te bepalen in de cerebrospinale vloeistof (CSF) en in het perifere bloed (PB), 
bestudeerden we 67 patiënten met definitief MS die behandeld werden met IVMP 
(Hoofdstuk 3). Ze werden geclassificeerd naar het ziekteverloop; 32 waren chronisch 
progressieve (CP) patiënten, 25 exacerberend-remitterend (RR) en 10 met een chronisch 
progressief ziekteverloop gepaard gaande met exacerbaties en remissies (CP+RR). De 
MS patiënten werden behandeld met 1000 mgr intraveneus MP tijdens 10 opeenvolgende 
dagen. Voor en na IVMP behandeling bepaalden we gelijktijdig in CSF en PB CD3+, 
CD4+, CD8+, CD20+ en Ial+ lymfocyten subpopulaties. Kurtzke's EDSS werd 
gebruikt voor de klinische evaluatie. De mate van ziekte-progressie werd gedefinieerd als 
de ratio van de EDSS en de ziekteduur. Dertien patiënten met een lumbale hernia nuclei 
pulposi werden onderzocht als controles. 
Voorafgaand aan de IVMP behandeling vonden we bij MS patiënten, met name bij de CP 
groep, significant lagere CD4+ T-cel percentages in het PB in vergelijking met de 
controle-groep (p<0,05). Het percentage van CD4+ T-cellen in de CSF van MS 
patiënten was signifikant hoger vergeleken met het PB (p=0,0001), en neigde tot hogere 
waarden in vergelijking met de controle-groep (p=0,072). Het aantal mononucléaire 
cellen in de CSF was significant gecorreleerd met hogere percentages van CSF CD3+ 
(r=0,40) en CD4+ (r=0,47) T-cellen en lagere CSF CD8+ (r=-0,33) T-cel percen-
tages. De percentages van B-cellen bij alle MS groepen in de CSF waren signifikant 
verhoogd vergeleken met de controles. Er kon geen relatie worden gevonden tussen de T-
of B-cel subpopulaües en de EDSS of met de mate van ziekte-progressie. Na de IVMP 
behandeling was er een significante afname van CD8+ T-cel percentages in het PB en 
tegelijkertijd een toename van het percentage CD8+ T-cellen in de CSF, gemeten bij de 
totale MS groep, en bij de CP en RR MS patiënten. Behalve voor de CP+RR MS 
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patiënten, lieten de CD4+ T-celpercentages in het PB of CSF geen signifikante 
veranderingen zien na behandeling. Onze bevindingen ondersteunen de opvatting dat bij 
MS, IVMP het inflammatoire proces van demyelinisatie zou kunnen beïnvloeden door 
haar selectieve en dissociatieve effect op T-supressor/cytotoxische cellen in het PB en 
CSF. 
Aangezien verscheidene studies enerzijds een associatie tussen vitamine B12-deficiëntie en 
MS hebben aangetoond en anderzijds een verband tussen het vitamine B12/foliumzuur 
metabolisme en myelinisatie werd het effect van IVMP op deze vitaminen bij MS 
onderzocht {Hoofdstuk 4). Eenentwintig patiënten (15 vrouwen, 6 mannen) met definitief 
MS werden behandeld met 1000 mgr intraveneus MP-succinaat dagelijks gedurende 10 
opeenvolgende dagen. Voor IVMP behandeling was er een negatieve correlatie (r=-0,59 , 
p=0,0084) tussen het vitamine B12 in het PB en de ziekte-progressie, gedefinieerd als de 
ratio van de EDSS en de ziekteduur. Een significante afname in de concentraties werd 
aangetoond in de CSF en in het PB van foliumzuur en in de CSF van vitamine B12 na 
IVMP behandeling. De afname in de concentratie van vitamine B12 in het PB was niet 
statistisch signifikant. Na Г МР behandeling waren alle mediane concentraties van 
vitamine BI2 en het foliumzuur onder de referentie-waarden. Een mogelijkheid zou zijn, 
dat verlaagde vitamine B12/foliumzuur concentraties bij MS patiënten het gevolg zijn van 
eerdere corticosteroïdbehandelingen. Anderzijds een meer causaal verband tussen 
verlaagde vitamine B12/foliumzuur concentraties en MS kan niet uitgesloten worden. 
Verder onderzoek is nodig om meer inzicht te verkrijgen in het vitamine Bi2 en 
foliumzuur metabolisme bij patiënten met MS. 
Seriële magnetische resonantie afbeeldingen (MRI) met contrast (gadolinium-DTPA) van 
het cerebrum tonen dikwijls nieuwe laesies bij MS patiënten, die geen bijkomende 
klinische klachten en verschijnselen tonen (klinisch "stille" en nieuwe laesies). Het belang 
van het vervolgen van de activiteit van de ziekte bij MS patiënten zal toenemen indien 
nieuwe therapieën voor MS ontwikkeld worden. Wij bestudeerden seriële MRI's met 
contrast van exacerberend-remitterende MS patiënten om de MR kenmerken te bepalen 
die de ziekte-activiteit aangeeft in deze subgroep van patiënten, en om MRI en de 
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klinische bevindingen met elkaar te kunnen vergelijken (Hoofdstuk S). Zeven patiënten 
met exacerberend-remitterende MS werden maandelijks gedurende 4-12 maanden 
onderzocht. Een totaal van 58 T2-gewogen en Τ,-gewogen MRT s zonder contrast werden 
verkregen. MRI's vertoonden nieuw aankleurende laesies bij 6 van de 7 patiënten. Bij 25 
(43%) van de 58 Τ,-gewogen MRI's met contrast werd een totaal van 50 nieuw 
aankleurende laesies gezien en op 1 afbeelding was een opnieuw aankleurende laesie te 
zien. De T2-gewogen afbeeldingen zonder contrast vertoonden overeenkomstige 
afwijkingen bij 92% van de nieuw aankleurende laesies. Bij de follow-up kleurden de 
meeste laesies (86%) maar één keer aan; 4% kleurden aan bij meer dan twee opeen-
volgende maandelijkse MRI's. Negenenveertig procent van de laesies gezien op T2-
gewogen afbeeldingen "verdwenen" (boven het resolutievermogen van het afbeeldings-
systeem) na een gemiddelde follow-up van 3,5 maand, in het bijzonder de laesies die bij 
aanvang kleiner dan 5 mm waren. Tijdens het onderzoek kwamen slechts 5 klinische 
exacerbaties bij 3 patiënten voor (alle op het moment dat de MRI met contrast 
aankleurende laesies toonde); de klinische toestand c.q. mate van invaliditeit veranderde 
niet van de patiënten. Bovendien toonde de MRI bij 21 gelegenheden nieuw aankleurende 
laesies of aankleuringen van oude laesies bij patiënten, die klinisch stabiel waren (4,2 
keer meer klinisch "stille" ziekte-aktiviteit). Het resultaat duidt er op, dat MRI met 
contrast gevoeliger is dan de klinische evaluatie als het gaat om de beoordeling van 
ziekte-activiteit bij patiënten met exacerberend-remitterend MS, en dat MRI nuttig kan 
zijn bij de evaluatie van de effecten van verschillende behandelingsvormen. 
Hoofdstuk б en 7 behandelen het gebruik van MRI met contrast (gadolinium-DTPA) bij 
MS, met name bij de evaluatie van de ziekte-aktiviteit, en het effekt van Г МР hierop. 
Eén van de eerste fasen bij de plaque-ontwikkeling bij MS is waarschijnlijk de 
bloedhersenbarrière (BBB) disruptie. Deze fase kan gevisualiseerd worden door de MRI 
met gadolinium van de hersenen. Seriële MRI studies bij MS laten een continu spectrum 
van ziekte-aktiviteit zien met komen en gaan van acute laesies, zelfs bij klinisch stabiele 
MS patiënten. IVMP heeft een gunstig klinisch effekt en vermindert de gadolinium-
aankleuring, wat aangeeft, dat de bloedhersenbarrière (BBB) integriteit verbetert; IVMP 
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vermindert de intrathecale immunoglobulinensynthese met een reductie van het CSF MBP 
bij MS patiënten. In een prospectieve studie (Hoofdstuk 6) vergeleken we het aantal 
gadolinium-DTPA aankleurende laesies op de MRI met de CSF en klinische bevindingen 
voor en na behandeling met IVMP bij exacerberende MS patiënten. Twintig 
behandelingen werden in totaal gegeven. Voor behandeling was er een signifikante 
correlatie tussen gadolinium-DTPA aankleuring (gezien op 16/20 scans) en CSF MBP. 
Als de aankleuring met gadolinium-DTPA ontsteking betekent en het CSF MBP myeline-
afbraak aangeeft, dan zou de mate van "inflamed tissue" moeten correleren met de hoogte 
van de myéline afbraak. Klinische verbetering trad op tijdens IS van de 20 behandelingen 
en afname van gadolinium-DTPA aankleuring op 12 van de 16 scans; het gemiddelde 
CSF MBP was de enige CSF variabele die onder de referentie-waarde daalde na 
behandeling. Er was een signifikant gecorreleerd trias tussen de afname in CSF MBP en 
gadolinium-DTPA aankleuring en de afname in klinische invaliditeit. Derhalve gaat het 
klinische effekt van methylprednisolon gepaard met een reduktie van ontsteking en 
myéline afbraak. Een gecorreleerd trias wordt gevonden tussen gadolinium-aankleuring, 
klinische verbetering en afname van het CSF MBP na IVMP behandeling, hetgeen een 
verband aantoont tussen het herstel van de BBB integriteit, de klinische verbetering, en 
afname van de myéline afbraak. Het is niet duidelijk, in hoeverre MP voornamelijk 
interfereert met het proces van de demyelinisatie zelf of meer aspecifiek reageert met haar 
mediatoren. 
Het laatste deel van dit proefschrift (Hoofdstuk 8 en 9) gaat over de evaluatie van IVMP 
therapie bij MS op lange termijn, vastgesteld door lange termijn MRI follow-up, klinische 
evaluatie en verschillende CSF bepalingen gedurende de follow-up. In een longitudinale 
prospektieve studie (Hoofdstuk 8), volgden we 46 patiënten (17 mannen, 29 vrouwen) met 
definitief MS, die behandeld werden met IVMP. Negentien patiënten hadden een 
chronisch progressief (CP) ziekteverloop, 19 patiënten hadden exacerberende-remitterende 
(RR) MS, en 8 patiënten hadden een gemengd (CP+CR) ziekteverloop. De gemiddelde 
follow-up periode was 2,6 jaar (bereik 1,7-3,5 jaar). Alle patiënten werden behandeld 
voor een symptomatische verslechtering. Onafhankelijk van het ziekteverloop, toonden 
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65% van de 46 MS patiënten (30/46) een klinische verbetering na de eerste IVMP 
behandeling, gedefinieerd als een daling op de EDSS met 1,0 punt of meer. Tijdens de 
follow-up periode werden in totaal 59 IVMP behandelingen gegeven (variërend van 0 tot 
5 behandelingen per patiënt); 8 patiënten werden behandeld met een combinatie van 
cyphosphamide en prednison, in verband met sterke progressieve achteruitgang. Tijdens 
de follow-up periode toonden 19 patiënten (41%) een toename op de EDSS (1,0 punt of 
meer) vergeleken met de EDSS-score direct na de eerste IVMP; 22 patiënten (48%) 
hadden geen veranderingen op de EDSS en 5 patiënten (11%) toonden een klinische 
verbetering (afname van 1.0 punt of meer op de EDSS). Bij de exacerberende MS 
patiënten (RR en CP+RR, n=38) was de gemiddelde exacerbatie-frequentie per patiënt 
per jaar voor de eerste IVMP behandeling 2,6 , die signifikant (ρ <0,0001) afnam tot 0,8 
tijdens de follow-up periode. Statistisch werd er geen signifikant verschil gezien tussen de 
baseline EDSS en EDSS na de follow-up periode bij exacerberende MS patiënten. Bij de 
CP MS patiënten was de klinische achteruitgang (toename van 1,0 punt of meer op de 
EDSS) tijdens de follow-up periode het meest opvallend: 11 (58%) van de CP MS 
patiënten gevolgd door 3 (37,5 %) van de CP+RR MS groep. Klinische achteruitgang 
trad het minste op bij de RR MS patiënten (26% ; 5/19). Na de follow-up periode werd 
een signifikante toename (p<0,05) in de gemiddelde EDSS-score gezien bij de chronisch 
progressieve (CP en CP+RR) MS patiënten in vergelijking met de baseline EDSS-score 
(3,8 tot 4,6). De CSF variabelen (mononucléaire cellen, MBP, oligonaie banden bij iso-
electrisch focusing (IEF), IgG index en intrathecale IgG synthese) namen signifikant af na 
de initiële IVMP. Na de follow-up periode toonden alle variabelen een blijvende afname 
qua concentratie in vergelijking met de concentraties voorafgaand aan de eerste Г МР. 
Onze studie duidt erop, dat (herhaalde) IVMP de exacerbatie-frequentie bij exacerberende 
MS patiënten terugbrengt, ofschoon toename van invaliditeit bij exacerberende MS niet 
kan worden verhinderd. Bij chronisch progressieve MS lijkt (herhaalde) Г МР de 
klinische verslechtering niet te verminderen in vergelijking met het natuurlijk beloop. 
Aanhoudende effekten worden gevonden in de CSF van MS patiënten behandeld met 
IVMP, 1,6 jaar na het begin van de eerste behandeling. 
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Samenvatting en conclusies 
In Hoofdstuk 9 voerden we seriële MRT s uit na Г МР om te onderzoeken of het 
onderdrukken van de gadolinium-aankleuring persisteert en of daarmee in verband staande 
afwijkingen op T2-gewogen beelden na behandeling verdwijnen. Dertien patiënten met 
definitief MS kregen een totaal van 31 behandelingen met MP tijdens een gemiddelde 
periode van 50 weken. MR scans met gadolinium werden vervaardigd voor en na 
behandeling en dan met maandelijkse tussenpozen met gebruik van een gestandaar-
diseerde "slice repositioning" en scan-protocol. Tijdens het onderzoek werden 609 aktieve 
laesies ontdekt op een totaal van 195 scans. Vijftien procent van de aktieve laesies zouden 
zijn gemist zonder de toediening van gadolinium. Direkt na behandeling was de reductie 
in het aantal aankleurende laesies 78%, wat een teken van herstel is van de BBB en een 
remming van het ontstekingsproces aangeeft. Bij follow-up werd hernieuwde aankleuring 
van oude laesies maar sporadisch gezien. Er werd geen gunstig effekt gezien ten aanzien 
van de mate van verdwijnen van gerelateerde afwijkingen op de T2-gewogen beelden, een 
teken van persisterende weefselverandering (bijvoorbeeld oedema, cellulaire infiltratie of 
demyelinisatie). Het effekt van IVMP behandeling op de MRI met gadolinium is tijdelijk, 
met een gemiddeld MRI effekt van 9,7 weken. 
Conclusies 
De behandeling met hoge dosis intraveneus methylprednisolon (IVMP) is een veilige en 
zinvolle therapie bij de behandeling van exacerberende en progressief verlopende MS. 
IVMP vermindert de intrathecale immunoglobulinensynthese en het myéline basisch 
proteïne in de cerebrospinale vloeistof, en vermindert het aantal gadolinium-aankleurende 
laesies op de MRI van het cerebrum. Bovendien lijkt IVMP een selektief effekt te hebben 
op suppressor/cytotoxische cellen bij MS. Al deze mechanismen leiden tot een remming 
van het ontstekingsproces en van myéline afbraak, wat op haar beurt uiteindelijk ten 
grondslag ligt aan het bewerkstelligen van klinische verbetering. De resultaten van IVMP 
behandeling op lange termijn bij MS, vergeleken met het natuurlijk verloop van de ziekte, 
zijn minder overtuigend, maar persisterende effekten van verminderde ontsteking in de 
cerebrospinale vloeistof wordt gevonden bij MS patiënten, die behandeld zijn met IVMP. 
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I 
High-dose intravenous methylprednisolone has a beneficial effect in MS, especially in the 
management of acute exacerbations of MS. (This thesis) 
II 
High-dose intravenous methylprednisolone is a safe, efficient and acceptable mode of 
steroid administration in MS. (This thesis; Thompson et al. Neurology 1989; 39: 969-
971) 
ΙΠ 
In relapsing MS, the clinical effect of high-dose intravenous methylprednisolone is 
accompanied by a reduction of inflammation and myelin breakdown, measured by the 
immunoglobulin synthesis and myelin basic protein (MBP) in the cerebrospinal fluid 
respectively. (This thesis) 
IV 
In MS high-dose intravenous methylprednisolone reduces gadolinium enhancement on 
magetic resonance imaging (MRI) of the brain, which indicates suppression of active 
inflammation, and restoration of the disturbed blood-brain-barrier. (This thesis) 
V 
The level of myelin basic protein (MBP) in the cerebrospinal fluid of MS patients 
provides a sensitive parameter of the amount of myelin breakdown. (This thesis) 
VI 
Gadolinium-enhanced MRI of the brain is an useful indicator for disease activity in MS, 
and it can be applied to monitor treatment effects in MS. (This thesis) 
VII 
The role of the vitamin B12 /folate metabolism in MS and in myelin formation is more 
important than accepted at this moment. (This thesis) 
VIII 
In the Netherlands there is a special need for MS health centres. 
IX 
Interferon beta seems to alter the natural history in relapsing MS in a favourable way. 
(The IFNB Multiple Sclerosis Study Group. Neurology 1993; 43: 655-661; Paty et al. 
Neurology 1993; 43: 662-667). 
X 
Despite new promising techniques in neurology, neurosurgery and related areas in the last 
decades, the overall life expectancy and quality of life for glioblastoma multiforme is still 
rather poor. 
XI 
Truth cannot be found by aspiring excessively after honour and great wisdom but only 
with fantasy in life. 



